Fact-checked by Grok 2 weeks ago

Biotechnology

Biotechnology is the application of biological systems and organisms to technical and industrial processes, utilizing living cells, enzymes, or derivatives to produce or modify products for practical uses such as medicine, agriculture, and manufacturing.^[1] This interdisciplinary field integrates principles from biology, chemistry, and engineering, evolving from ancient practices like fermentation for bread and beer production to modern techniques including recombinant DNA technology developed in the 1970s.^[2] Key applications span medical biotechnology, which enables production of therapeutic proteins like insulin via genetically engineered bacteria, reducing reliance on animal sources and improving treatment for diabetes; agricultural biotechnology, which has engineered crops resistant to pests and herbicides, thereby increasing yields and decreasing pesticide use; and industrial biotechnology, which employs microbes for biofuel production and waste remediation.^[3] Notable achievements include the first commercial recombinant human insulin in 1982, marking the advent of biologics as a major pharmaceutical category, and the rapid development of mRNA vaccines during the COVID-19 pandemic, demonstrating biotechnology's capacity for swift response to global health threats through scalable, targeted immune modulation.^[4] In agriculture, genetically modified organisms (GMOs) have contributed to a 22% increase in crop yields on average since their introduction, with empirical data from field trials and meta-analyses confirming reduced environmental impacts via lower chemical inputs without evidence of health risks beyond those of conventional breeding.^[5]^[6] These advances stem from foundational discoveries like the structure of DNA in 1953 and gene cloning techniques, enabling precise genetic manipulation that underpins tools such as CRISPR-Cas9 for genome editing since 2012.^[3] Despite these successes, biotechnology faces controversies, particularly surrounding GMOs and human genetic engineering, where public apprehension often persists despite rigorous safety assessments showing equivalence to non-GMO counterparts in nutritional and toxicological profiles; such concerns are frequently amplified by advocacy groups but lack substantiation in long-term epidemiological studies.^[7]^[6] Ethical debates also arise over applications like germline editing, which could introduce heritable changes, raising questions of unintended ecological or societal consequences, though proponents argue that first-principles risk assessment favors innovation under controlled empirical validation. Regulatory frameworks, varying by jurisdiction, aim to balance these risks with benefits, as seen in approvals for gene therapies treating rare diseases. Overall, biotechnology's causal impacts—evidenced by enhanced food security, novel therapeutics, and sustainable processes—underscore its role in addressing pressing global challenges, provided advancements prioritize verifiable data over unsubstantiated fears.^[8]^[4]

Fundamentals

Definition and Scope

Biotechnology is defined as the application of science and technology to living organisms, as well as parts, products, and models thereof, to alter living or non-living materials for the production of knowledge, goods, and services.^[9] This formulation, established by the Organisation for Economic Co-operation and Development (OECD) in 1997, emphasizes the manipulation of biological systems for practical outcomes across diverse sectors.^[9] The field integrates principles from biology, chemistry, genetics, and engineering to harness cellular and biomolecular processes.^[10] The term "biotechnology" was coined in 1919 by Hungarian engineer Károly Ereky, who used it to describe the production of products from raw materials with the aid of living organisms, initially in the context of agricultural advancements like intensified animal husbandry.^[11] Ereky envisioned biotechnology as a systematic approach to leveraging biological agents for industrial-scale transformation, distinguishing it from ad hoc traditional practices such as fermentation.^[3] The scope of biotechnology spans multiple disciplines and applications, including medical uses for therapeutics and diagnostics, agricultural improvements via genetically modified organisms, industrial processes for sustainable manufacturing, and environmental solutions like bioremediation.^[12] Core activities involve techniques such as genetic engineering, tissue culture, and bioprocessing, enabling innovations from insulin production in bacteria—first achieved in 1978—to CRISPR-based genome editing patented in 2012.^[13] While early biotechnology relied on selective breeding and microbial fermentation dating back millennia, modern biotechnology, post-1970s, focuses on recombinant DNA and synthetic biology for precise molecular interventions.^[2] This breadth positions biotechnology as a foundational technology addressing global challenges in health, food security, and resource efficiency, though ethical and regulatory considerations delimit its implementation in areas like human germline editing.^[14]

Core Principles

Biotechnology is grounded in the manipulation of biological systems to achieve practical outcomes, primarily through two interconnected principles: genetic engineering and bioprocess engineering. Genetic engineering entails the deliberate alteration of an organism's genetic material to confer desired traits or synthesize specific biomolecules, relying on recombinant DNA technology. This involves isolating a target gene, incorporating it into a vector like a plasmid using restriction enzymes to cut DNA and ligase to seal fragments, and introducing the construct into a compatible host cell, such as bacteria or yeast, for replication and expression.^[15]^[2] The efficacy of genetic engineering stems from the central dogma of molecular biology, which describes the flow of genetic information from DNA via transcription to messenger RNA and translation into proteins, allowing precise interventions at the genomic level. Host organisms are selected for their ability to maintain the recombinant DNA through cell division and express the foreign gene phenotypically, as exemplified by the production of human insulin in Escherichia coli since the late 1970s. Selectable markers, such as antibiotic resistance genes, ensure only transformed cells survive, facilitating identification and propagation.^[2]^[16] Bioprocess engineering complements genetic manipulation by enabling scalable production of biotechnological outputs. This principle involves cultivating engineered or natural organisms in controlled environments, such as stirred-tank bioreactors, under optimized conditions of pH, temperature, oxygen levels, and nutrients to maximize yield. Sterility is paramount to prevent contamination, with downstream processing steps like centrifugation, filtration, and chromatography purifying products such as enzymes, vaccines, or monoclonal antibodies. Fermentation technology, a foundational bioprocess, harnesses microbial metabolism for metabolite production, as in penicillin synthesis using Penicillium fungi scaled industrially since the 1940s.^[15]^[16] These principles integrate biological specificity—where enzymes and cellular machinery perform reactions with high fidelity—with engineering scalability, drawing on the inherent capabilities of living systems for efficient, targeted catalysis unattainable by purely chemical means. Advances like CRISPR-Cas9 have refined genetic engineering since 2012, enhancing precision in gene editing while bioprocess innovations, including single-use bioreactors, improve efficiency and reduce costs in industrial applications.^[16]^[17]

Key Techniques and Tools

Recombinant DNA technology, pioneered in 1972 by Paul Berg and further developed by Stanley Cohen and Herbert Boyer, enables the combination of genetic material from different sources using restriction endonucleases to cut DNA at specific sequences and DNA ligase to join fragments, often inserting them into plasmid vectors for propagation in host cells like Escherichia coli.^[18]^[19] This technique forms the basis for producing recombinant proteins, such as human insulin first achieved in 1978 by Genentech.^[20] The polymerase chain reaction (PCR), invented in 1983 by Kary Mullis at Cetus Corporation, amplifies targeted DNA segments exponentially through repeated cycles of thermal denaturation, primer annealing, and DNA polymerase extension, typically using thermostable *Taq* polymerase isolated from Thermus aquaticus.^[21]^[22] By 1985, refinements allowed automated cycling, revolutionizing diagnostics, forensics, and cloning; a single PCR run can generate billions of copies from nanogram quantities of starting material in under two hours.^[23] CRISPR-Cas9 genome editing, adapted from the bacterial adaptive immune system and demonstrated for eukaryotic use in 2012 by Jennifer Doudna, Emmanuelle Charpentier, and colleagues, employs a single-guide RNA (sgRNA) to direct the Cas9 endonuclease to cleave DNA at precise loci, inducing double-strand breaks repaired via non-homologous end joining or homology-directed repair for insertions, deletions, or substitutions.^[24]^[25] This programmable tool offers higher specificity and efficiency than prior methods like zinc-finger nucleases, enabling applications from crop improvement to therapeutic gene correction, though off-target effects remain a challenge requiring variants like high-fidelity Cas9.^[26] Bioreactors, essential for industrial-scale bioprocessing, maintain optimal conditions—such as pH 6-7, temperatures of 30-37°C, and dissolved oxygen levels via sparging and agitation—for microbial or mammalian cell growth, yielding products like antibiotics or vaccines through batch, fed-batch, or continuous fermentation modes.^[27] Stirred-tank designs predominate, scaling from lab volumes of liters to commercial capacities exceeding 20,000 liters, with engineering principles ensuring mass transfer and shear stress do not inhibit yields.^[28] Monoclonal antibody production via hybridoma technology, developed in 1975 by Georges Köhler and César Milstein, involves immunizing animals, fusing antigen-specific B cells with immortal myeloma cells using polyethylene glycol, and selecting clones via HAT medium to yield stable, homogeneous antibody secreters screened for affinity.^[29] Modern refinements include recombinant expression in CHO cells and phage display for humanized variants, supporting therapeutics like rituximab approved in 1997, with global production exceeding 500 metric tons annually by 2020.^[30] Additional tools include DNA microarrays, which hybridize labeled nucleic acids to immobilized probes on chips to quantify gene expression or polymorphisms, enabling high-throughput genomics since their commercialization in the late 1990s.^[13] These techniques collectively underpin biotechnology's capacity for precise molecular manipulation, though their efficacy depends on empirical validation amid potential biases in academic reporting favoring positive outcomes.^[31]

Historical Development

Ancient and Pre-Modern Biotechnology

![Sixteenth-century engraving of a brewer by Jost Amman]float-right Biotechnology in ancient times primarily involved empirical manipulation of biological processes through selective breeding and microbial fermentation, predating scientific understanding of genetics and microbiology. During the Neolithic Revolution, circa 10,000–9000 BCE in the Fertile Crescent, humans domesticated wild plants such as emmer wheat and barley by selecting for traits like non-shattering seed heads and larger grains, transforming them into staple crops that supported sedentary societies.^[32] Animal domestication followed, with sheep and goats bred around 9000–8000 BCE for meat, milk, and wool, involving intentional selection for heritable traits that enhanced productivity.^[33] These practices constituted early genetic engineering via artificial selection, yielding domesticated varieties distinct from their wild progenitors, such as teosinte evolving into maize through selective breeding between 6000 and 10,000 years ago in Mesoamerica.^[32] Fermentation emerged as a key ancient biotechnological technique for food preservation and production, harnessing microorganisms without knowledge of their role. Beer brewing evidence dates to 9000–8000 BCE in the Near East, where barley fermentation produced alcoholic beverages using ambient yeasts, with Sumerian and Babylonian records confirming practices by 7000 BCE.^[33] In Egypt by 4000 BCE, yeast-mediated leavening revolutionized bread-making, while similar processes yielded wine from grapes fermented around 6000 BCE in regions like the Caucasus. Dairy biotechnology included yogurt and cheese production starting circa 6000 BCE, relying on lactic acid bacteria to ferment milk, with cheese-making traced to 7000–4000 years ago through animal milk processing.^[34] Pre-modern advancements built on these foundations, incorporating refined selective breeding and fermentation in medieval Europe and Asia. By the 13th–14th centuries, European agriculture featured three-field crop rotation and improved livestock breeds through continued selection, enhancing yields and resilience.^[35] In China, fermentation techniques for soy products like miso and tempeh, developed over millennia, utilized fungi and bacteria for protein preservation, while sericulture—selective breeding of silkworms for silk—dates to around 2700 BCE, involving controlled rearing and genetic propagation of Bombyx mori.^[36] These methods, grounded in observable cause-and-effect without mechanistic insight, laid empirical groundwork for later scientific biotechnology by demonstrating biological systems' manipulability for human benefit.^[32]

Modern Foundations (19th-20th Century)

The foundations of modern biotechnology emerged in the 19th century through advances in microbiology and understanding microbial processes. Louis Pasteur's experiments in the 1850s and 1860s demonstrated that specific microorganisms cause particular types of fermentation, refuting spontaneous generation and establishing that yeast ferments sugar into alcohol and carbon dioxide under anaerobic conditions.^[37] In 1862, Pasteur developed pasteurization, heating wine and beer to 60–70°C to kill spoilage microbes while preserving quality, a process later applied to milk in 1882 to reduce tuberculosis transmission via contaminated dairy.^[38] These findings shifted fermentation from empirical craft to scientifically controlled processes, enabling reliable industrial applications.^[39] A pivotal biochemical breakthrough occurred in 1897 when Eduard Buchner extracted zymase, an enzyme from yeast cells, and showed it could ferment sugar into alcohol without intact living cells, disproving vitalism—the notion that fermentation required a "life force."^[40] This cell-free fermentation earned Buchner the 1907 Nobel Prize in Chemistry and laid the groundwork for enzymology, revealing that non-living extracts could catalyze complex reactions, which influenced subsequent enzyme isolations and industrial biocatalysis.^[41] Concurrently, genetics provided a hereditary framework: Gregor Mendel's 1866 publication of pea plant hybridization experiments outlined the laws of segregation and independent assortment, positing discrete heritable units (later genes) that predict trait ratios like 3:1 in monohybrids, though overlooked until rediscovery in 1900.^[42] These principles enabled selective breeding advancements in agriculture and foreshadowed genetic manipulation.^[43] Industrial biotechnology scaled during World War I, exemplified by Chaim Weizmann's 1916 anaerobic fermentation process using Clostridium acetobutylicum bacteria to convert starch from corn or potatoes into acetone, yielding up to 30% of fermentable substrate as product.^[44] This met Britain's demand for acetone in cordite production—over 10,000 tons annually by 1918—after German submarine blockades cut wood-derived supplies, with factories in Britain and later the U.S. producing millions of gallons via submerged fermentation.^[45] Post-war, such microbial processes expanded to solvents like butanol. In pharmaceuticals, Alexander Fleming's 1928 observation of Penicillium rubens mold secreting a substance inhibiting Staphylococcus growth marked antibiotic discovery; he isolated penicillin and published findings in 1929, though purification scaled only in the 1940s.^[46]^[47] By 1919, aerobic fungal fermentation produced citric acid via Aspergillus niger, initiating large-scale organic acid manufacturing.^[4] These developments integrated microbiology, enzymology, and genetics into applied biotechnology, transitioning from artisanal to engineered bioprocesses.

Recombinant DNA Era (1970s-1990s)

The development of recombinant DNA technology in the early 1970s revolutionized biotechnology by enabling the deliberate combination and propagation of genetic material from disparate sources. In 1972, researchers David Jackson, Robert Symons, and Paul Berg created the first chimeric DNA molecule by ligating SV40 viral DNA to lambda phage DNA, demonstrating the feasibility of joining DNA fragments in vitro.^[48] Building on this, in November 1972, Stanley Cohen of Stanford University and Herbert Boyer of the University of California, San Francisco, collaborated to insert antibiotic resistance genes from one bacterial plasmid into another using EcoRI restriction enzyme and DNA ligase, producing stable recombinant plasmids that replicated in Escherichia coli host cells.^[18]^[49] Their 1973 experiments marked the first successful cloning of recombinant DNA in a living organism, laying the groundwork for gene manipulation across species.^[50] Concerns over biosafety risks, including unintended gene transfer or pathogen creation, led to proactive self-regulation by scientists. In July 1974, key figures including Berg, Cohen, and Boyer called for a voluntary moratorium on certain recombinant experiments until risks could be assessed.^[51] This culminated in the February 1975 Asilomar Conference on Recombinant DNA Molecules, attended by over 140 scientists, where participants classified experiments by risk levels and recommended physical and biological containment measures, such as using disabled host-vector systems.^[52] The conference's recommendations directly informed the U.S. National Institutes of Health's 1976 Recombinant DNA Research Guidelines, which standardized protocols and permitted low-risk experiments to resume, balancing innovation with precaution.^[53] Commercialization accelerated in the late 1970s, transforming recombinant DNA from a research tool into an industrial platform. Boyer co-founded Genentech in 1976 with venture capitalist Robert Swanson to exploit the technology for protein production.^[54] In August 1978, Genentech researchers, led by Dennis Kleid, achieved the first laboratory synthesis of human insulin via recombinant methods, expressing synthetic A and B chain genes separately in E. coli and combining them chemically.^[55]^[56] This effort, in collaboration with Eli Lilly, yielded Humulin, approved by the FDA in October 1982 as the first recombinant therapeutic protein, reducing reliance on animal-derived insulin and enabling scalable production.^[57] The Cohen-Boyer technique, patented in 1980 after a 1974 application, was licensed non-exclusively by Stanford and UCSF, generating over $255 million in royalties by 1997 and fueling dozens of biotech startups.^[58] The 1980s and 1990s saw expanded applications, including recombinant human growth hormone (somatropin, approved 1985 for treating deficiency disorders), interferon alfa-2b (Intron A, approved 1986 for cancers and hepatitis), hepatitis B vaccine (Recombivax HB, approved 1986), and tissue plasminogen activator (Activase, approved 1987 for thrombolysis).^[59] These products demonstrated recombinant DNA's capacity for producing complex eukaryotic proteins in prokaryotic systems, though challenges like glycosylation required later shifts to mammalian cell expression. By the 1990s, the technology underpinned gene therapy trials, with the first approved human trial in 1990 for severe combined immunodeficiency using retroviral vectors to insert corrective genes.^[48] Overall, the era established biotechnology as a distinct industry, with global market growth from nascent ventures to over 1,300 companies by 1999, driven by therapeutic outputs exceeding $10 billion annually.^[60]

Genomics and Beyond (2000s-Present)

The completion of the Human Genome Project in April 2003 marked a pivotal milestone, providing the first reference sequence of the human genome and enabling comprehensive genomic analysis.^[61] This international effort, launched in 1990, sequenced approximately 92% of the euchromatic portion of the genome by 2003, laying the groundwork for subsequent biotechnological innovations by identifying genes and regulatory elements.^[62] Advances in next-generation sequencing (NGS) technologies, emerging in the mid-2000s, dramatically accelerated genomic research by enabling parallel sequencing of millions of DNA fragments. The 454/Roche platform, introduced commercially in 2005 based on pyrosequencing, represented an early NGS system, followed by platforms from Illumina and others that reduced sequencing throughput times and costs.^[63] By 2022, the cost of sequencing a human genome had fallen to approximately $525 from over $95 million in 2001, driven by improvements in read length, error rates, and automation, facilitating large-scale projects like population genomics and cancer sequencing.^[64]^[65] Gene editing technologies advanced significantly with the adaptation of CRISPR-Cas9 in 2012, allowing precise, targeted modifications to DNA sequences in prokaryotic and eukaryotic cells. Originally observed as bacterial adaptive immunity mechanisms in the 1980s and 1990s, CRISPR-Cas9 was repurposed for genome engineering through key experiments demonstrating its use as a programmable nuclease, outperforming prior methods like zinc-finger nucleases in efficiency and accessibility.^[66] This tool has enabled applications in functional genomics, such as knocking out specific genes to study loss-of-function effects, though off-target edits remain a challenge requiring ongoing refinements like high-fidelity variants.^[67] Synthetic biology expanded genomic capabilities by engineering novel biological systems, with milestones including the 2000 construction of synthetic genetic circuits like toggle switches in E. coli and the 2010 creation of the first synthetic bacterial cell by Craig Venter's team, which transplanted a chemically synthesized genome into a recipient cell.^[68] These developments integrated genomics with de novo design principles, enabling applications in biofuel production and metabolic engineering, where genomes are rewired to optimize pathways for industrial outputs.^[69] Messenger RNA (mRNA) technologies, building on genomic insights into protein coding, gained prominence in the 2010s for therapeutic delivery, culminating in the rapid deployment of mRNA-based COVID-19 vaccines in 2020 by Moderna and BioNTech/Pfizer, which encoded the SARS-CoV-2 spike protein to elicit immune responses without genomic integration.^[70] This approach leverages synthetic mRNA stabilized by modifications like nucleoside analogs, offering faster development than traditional vaccines and extending to oncology and infectious diseases.^[71] Personalized medicine has integrated genomics to tailor interventions based on individual genetic profiles, with pharmacogenomics guiding drug selection to avoid adverse reactions, as seen in FDA-approved tests for variants in genes like CYP2C19 affecting clopidogrel efficacy.^[72] Large-scale initiatives, such as the UK's 100,000 Genomes Project (2015-2018) and ongoing efforts in precision oncology, use NGS to identify actionable mutations, improving outcomes in cancers like BRCA-associated breast cancer through targeted therapies.^[73] These advancements underscore genomics' causal role in shifting biotechnology from broad-spectrum to variant-specific strategies, though equitable access remains limited by data biases and infrastructure costs.^[74]

Applications

Medical Biotechnology

Medical biotechnology applies biological systems, organisms, and derivatives to develop diagnostics, therapeutics, and preventive interventions for human health. Key areas include recombinant protein production, monoclonal antibodies, gene and cell therapies, and molecular diagnostics, enabling targeted treatments for genetic disorders, cancers, and infectious diseases. These technologies leverage techniques such as recombinant DNA and CRISPR-Cas9 to address underlying biological mechanisms, improving efficacy over traditional small-molecule drugs in many cases.^[4] Recombinant therapeutics represent a foundational achievement, with human insulin produced via genetically modified bacteria marking the first FDA-approved biotechnology-derived drug on October 28, 1982, as Humulin by Eli Lilly, following Genentech's 1978 synthesis.^[57] This innovation addressed supply limitations of animal-derived insulin and reduced immunogenicity risks, enabling scalable production through microbial fermentation. Monoclonal antibodies followed, with muromonab-CD3 (Orthoclone OKT3) approved in 1986 for preventing kidney transplant rejection, derived from hybridoma technology developed by Köhler and Milstein in 1975.^[75] Over 100 such antibodies have since gained approval, targeting cancers and autoimmune conditions via precise immune modulation.^[76] Gene and cell therapies have advanced for rare and genetic diseases, with hematopoietic stem cell transplantation established as the primary approved stem cell treatment for blood disorders like leukemia and aplastic anemia.^[77] CAR-T therapies, such as axicabtagene ciloleucel (Yescarta) approved in 2017, engineer patient T-cells to target B-cell lymphomas, achieving response rates exceeding 80% in refractory cases.^[77] Gene therapies show higher clinical success rates for orphan indications, with Phase 1 approval probabilities 48% above conventional drugs; Luxturna (2017) was the first for inherited retinal dystrophy, while Casgevy (2023) addressed sickle cell disease via ex vivo editing.^[78] ^[79] CRISPR-based trials, numbering over 150 by early 2025, target blood disorders, cancers, and diabetes, with in vivo editing demonstrating feasibility in Phase 1 studies for conditions like transthyretin amyloidosis.^[80] ^[81] Diagnostics in medical biotechnology rely on nucleic acid and protein detection methods for rapid, sensitive pathogen and biomarker identification. Polymerase chain reaction (PCR), invented in 1983, amplifies DNA for detecting genetic mutations and viruses, underpinning tests for conditions like cystic fibrosis and COVID-19.^[82] Enzyme-linked immunosorbent assay (ELISA) quantifies antigens or antibodies via immune reactions, widely used for HIV and hormone screening.^[83] DNA microarrays enable high-throughput gene expression profiling, aiding cancer subtyping and pharmacogenomics by hybridizing thousands of probes simultaneously.^[84] These tools have reduced diagnostic timelines from weeks to hours, enhancing early intervention.^[85]

Agricultural Biotechnology

Agricultural biotechnology applies scientific techniques, including genetic engineering and molecular breeding, to enhance crop and livestock production by modifying organisms for desirable traits such as pest resistance, herbicide tolerance, and improved nutritional profiles.^[86] These methods build on traditional selective breeding but enable precise alterations at the DNA level, allowing the introduction of genes from unrelated species to confer novel characteristics.^[87] Unlike conventional breeding, which relies on cross-pollination and selection over generations, modern approaches like recombinant DNA technology facilitate direct gene insertion, accelerating trait development.^[88] Core techniques include genetic engineering, where foreign DNA is inserted into plant genomes using vectors like Agrobacterium tumefaciens or gene guns, and marker-assisted selection (MAS), which uses DNA markers to identify and select plants carrying specific genes without altering the genome through transgenesis.^[89] MAS improves breeding efficiency by screening for traits like disease resistance early in development, reducing time from cross to commercialization.^[90] Additional tools encompass tissue culture for rapid propagation of elite varieties and CRISPR-based editing for targeted mutations, though the latter remains under regulatory scrutiny in many jurisdictions.^[91] Prominent applications involve insect-resistant crops like Bt corn and cotton, which express Cry proteins from Bacillus thuringiensis to target lepidopteran pests, reducing the need for chemical insecticides.^[92] Herbicide-tolerant varieties, such as Roundup Ready soybeans engineered with the CP4 EPSPS gene from Agrobacterium species, enable post-emergence weed control with glyphosate, simplifying farm management.^[93] These traits were first commercialized in 1996, with Bt cotton in the United States and China, and herbicide-tolerant soybeans following shortly after; by 1994, the Flavr Savr tomato marked the initial GMO market entry, though it achieved limited adoption.^[94]^[95] Other innovations include nutritionally enhanced crops, such as Golden Rice fortified with beta-carotene to combat vitamin A deficiency, and drought-tolerant maize varieties developed through MAS and transgenics for arid regions.^[96] Biofertilizers using engineered microbes, like rhizobia with improved nitrogen fixation, and biopesticides derived from microbial toxins support sustainable practices by minimizing synthetic inputs.^[97] Global adoption has expanded rapidly, with over 190 million hectares planted to GM crops by 2020, led by the United States where more than 90% of corn, soybeans, and upland cotton are genetically engineered.^[98] Empirical assessments indicate that GM crop adoption from 1996 to 2018 increased average yields by 22% and reduced insecticide applications by 37%, while boosting farmer incomes by 68% across adopting regions.^[99] In the U.S. maize and soybean sectors, GE varieties from 1998 to 2011 correlated with lower overall pesticide volumes despite rises in herbicide use for tolerant crops.^[100] These outcomes stem from reduced crop losses and labor efficiencies, though benefits vary by crop, region, and pest pressure.^[95]

Industrial Biotechnology

Industrial biotechnology applies biological systems, including enzymes and microorganisms, to manufacture chemicals, materials, fuels, and other products from renewable feedstocks, offering alternatives to petrochemical methods with potential reductions in energy use and emissions.^[101] Also termed white biotechnology, it emphasizes scalable processes like fermentation and biocatalysis for sustainable production across sectors such as food, detergents, and biofuels.^[102] This field has expanded since the late 20th century, driven by advances in genetic engineering that enable microbes to serve as efficient "cell factories."^[103] Key techniques include microbial fermentation, where bacteria, yeasts, or fungi convert substrates like glucose into target compounds in large bioreactors, and biocatalysis, utilizing enzymes to catalyze reactions under ambient conditions that minimize waste and energy inputs compared to chemical synthesis.^[104] Enzymes derived from extremophilic organisms, tolerant to high temperatures or pH, facilitate industrial-scale applications such as starch hydrolysis for glucose syrups, which supports over 90% of high-fructose corn syrup production globally.^[105] Fermentation processes, scalable via optimized strains, produce commodities like citric acid, with annual output exceeding 2 million tons primarily through Aspergillus niger cultures.^[106] Applications encompass biofuels, where Saccharomyces cerevisiae ferments biomass to yield bioethanol; in 2023, global production reached 114 billion liters, largely from biotechnological routes using corn or sugarcane.^[107] Biobased chemicals, including succinic acid for plastics via engineered E. coli, replace petroleum-derived equivalents, while enzymes from firms like Novozymes enhance detergent performance by breaking down stains at lower wash temperatures, reducing household energy use by up to 1 gigajoule annually per European consumer.^[108] Materials such as bioplastics from bacterial polyhydroxyalkanoates offer biodegradability, though scaling remains challenged by feedstock costs.^[109] The sector's market, valued at USD 585.1 million in 2024, projects growth to USD 1,467.82 million by 2033, fueled by regulatory incentives for bio-based products amid decarbonization efforts, though economic viability hinges on yield improvements and competition with fossil fuels.^[110] Leading companies include DSM for bio-ingredients and Solugen for hydrogen peroxide via engineered enzymes, demonstrating cost-competitive biosynthesis that undercuts traditional methods in select cases.^[111] Despite advantages in specificity and mild conditions, adoption faces hurdles from capital-intensive bioreactor infrastructure and variable raw material prices.^[112]

Environmental Biotechnology

Environmental biotechnology encompasses the application of biological organisms, processes, and systems—primarily microorganisms, plants, and enzymes—to address environmental challenges such as pollution remediation, waste treatment, and resource recovery.^[113] This field leverages natural metabolic pathways to degrade or transform contaminants into less harmful substances, offering a sustainable alternative to chemical or physical methods. Key processes include bioremediation, where microbes break down organic pollutants like hydrocarbons, and phytoremediation, utilizing plants to extract or stabilize heavy metals in soil.^[114] Unlike traditional remediation, which often requires energy-intensive excavation or incineration, environmental biotechnology operates under ambient conditions, minimizing secondary pollution.^[115] Bioremediation, a cornerstone technique, involves either biostimulation—adding nutrients to stimulate indigenous microbes—or bioaugmentation, introducing specialized strains to enhance degradation rates. In situ methods treat contaminants on-site without excavation, while ex situ approaches, such as biopiles or landfarming, involve relocation for controlled processing; the latter typically achieves higher success due to improved aeration and nutrient delivery.^[116] For instance, bacterial consortia like Pseudomonas species degrade petroleum hydrocarbons by oxidizing alkanes and aromatics into carbon dioxide and water. Mycoremediation employs fungi, such as white-rot species, to ligninolytic enzymes that dismantle persistent organics like pesticides.^[117] These methods have demonstrated efficacy in reducing total petroleum hydrocarbons by up to 1.2% per day in controlled studies.^[118] Notable applications include cleanup of oil spills, where bioremediation accelerated recovery post-Exxon Valdez incident in 1989, with nutrient additions boosting microbial activity on Alaskan shores. Similarly, during the 2010 Deepwater Horizon spill, dispersants combined with indigenous bacteria degraded over 200,000 tons of oil, though complete mineralization varied by depth and oxygen levels.^[118] In wastewater treatment, anaerobic digestion by methanogenic archaea converts organic sludge into biogas, recovering energy while reducing volume by 50-70%; activated sludge processes, enhanced by genetically selected microbes, remove nitrogen via denitrification at efficiencies exceeding 90% in municipal plants.^[119] For heavy metal contamination, biosorption using algal or bacterial biomass sequesters ions like cadmium and lead, with capacities reaching 100-200 mg/g in lab trials, though field scalability depends on pH and competing ions.^[114] Emerging advances integrate genetic engineering, such as CRISPR-edited microbes for targeted degradation of recalcitrant pollutants like PFAS, though regulatory hurdles limit deployment. Biosensors, employing enzyme-linked bacteria, enable real-time monitoring of toxins in water, detecting thresholds as low as parts per billion. Despite successes, efficacy hinges on environmental factors—temperature, bioavailability, and pollutant toxicity—often requiring hybrid approaches; for example, bioremediation struggles with chlorinated solvents without anaerobic priming. Overall, the field has treated millions of cubic meters of contaminated sites globally, with cost savings of 50-80% over physicochemical alternatives in applicable scenarios.^[114]^[120]

Impacts and Achievements

Economic and Societal Benefits

Biotechnology has driven substantial economic growth through expanded market revenues, job creation, and contributions to gross domestic product (GDP). The global biotechnology market reached USD 1.55 trillion in 2024, with projections estimating growth to USD 5.71 trillion by 2034 at a compound annual growth rate (CAGR) of approximately 13.9%.^[121] In the United States, the bioscience sector generated over $3.2 trillion in total economic output in 2023, encompassing direct industry activities and induced effects across supply chains.^[122] The U.S. biopharmaceutical industry alone supported $720 billion in value added to the economy as of recent analyses, equivalent to 3.4% of national GDP, through manufacturing, research, and related services.^[123] Employment impacts are notable, particularly in industrial applications. The U.S. industrial bioeconomy contributed $210.4 billion to GDP in 2023 while sustaining 643,992 domestic jobs in production, research, and support roles.^[124] These figures reflect biotechnology's role in high-value sectors like biomanufacturing, where processes such as enzyme-based production replace traditional chemical methods, yielding cost efficiencies and scalability.^[125] In Europe, the biotechnology industry added €34.5 billion in gross value added (GVA) to economic growth in 2018, with ongoing expansions in bioplastics and biofuels further amplifying fiscal returns.^[126] Societally, medical biotechnology has enhanced public health outcomes by enabling scalable production of therapeutics that reduce disease burdens and extend productive lifespans. Recombinant DNA techniques, introduced in the 1970s, facilitated mass production of human insulin starting in 1982, drastically lowering treatment costs and dependency on animal-derived sources, thereby improving diabetes management for millions.^[127] Vaccines developed via biotech platforms, including mRNA technologies deployed during the COVID-19 pandemic, have averted widespread mortality and morbidity, contributing to sustained life expectancy gains observed in the late 20th and early 21st centuries alongside antibiotics and diagnostics.^[127] These advancements correlate with broader reductions in infectious disease rates, allowing populations to allocate resources toward education and labor participation rather than acute care. In agriculture, genetically modified (GM) crops have bolstered food security by increasing yields and minimizing losses. From 1996 to 2020, biotech crops globally reduced pesticide applications by 748.6 million kilograms—a 7.2% decline—while boosting farmer incomes through higher productivity and resilience to pests and drought. This has supported caloric availability in developing regions, countering population pressures without proportional expansion of arable land.^[128] Industrial biotechnology further aids societal sustainability by optimizing resource use; for instance, microbial fermentation processes in chemical production have cut carbon dioxide emissions by up to 30%, resource consumption by 60%, and waste by 95% compared to petrochemical alternatives.^[129] Such efficiencies reduce environmental footprints, preserving ecosystems that underpin long-term human welfare.

Scientific Advancements

Biotechnology has propelled scientific progress by enabling precise manipulation of biological systems at the molecular level, yielding breakthroughs in genetics, protein engineering, and cellular biology. Recombinant DNA technology, pioneered in the 1970s through experiments splicing DNA from different organisms, allowed for the first time the creation of novel genetic constructs, fundamentally altering research capabilities in molecular biology.^[130] This innovation facilitated the production of human insulin via genetically modified bacteria in 1982, demonstrating biotechnology's capacity to synthesize complex proteins that were previously unobtainable in scalable quantities.^[3] The completion of the Human Genome Project in 2003 provided a complete reference sequence of the human genome, comprising approximately 3 billion base pairs, which accelerated discoveries in genomics and personalized medicine by enabling comprehensive mapping of genetic variations.^[131] Building on this, the adaptation of CRISPR-Cas9 as a programmable gene-editing tool in 2012 by Jennifer Doudna and Emmanuelle Charpentier transformed genome engineering, offering unprecedented precision and efficiency over prior methods like zinc-finger nucleases, with applications in correcting disease-causing mutations demonstrated in clinical trials for sickle cell disease by 2019.^[66]^[131] The technology's impact earned the 2020 Nobel Prize in Chemistry, underscoring its role in advancing causal understanding of gene function through targeted perturbations.^[66] Advancements in mRNA technology, rooted in decades of research on lipid nanoparticles for delivery, culminated in the rapid deployment of effective COVID-19 vaccines in late 2020, which elicited robust immune responses by instructing cells to produce viral spike proteins, thereby validating mRNA as a versatile platform for protein expression.^[132] This breakthrough extended to therapeutic applications, with mRNA-based approaches showing promise in cancer immunotherapy and rare genetic disorders by encoding corrective proteins transiently, bypassing permanent genomic alterations.^[132] Recent developments, such as single-cell DNA-RNA sequencing tools introduced around 2025, have further enhanced resolution in dissecting cellular heterogeneity, revealing non-coding regulatory elements that influence gene expression and disease pathology.^[133] In synthetic biology, directed evolution techniques have optimized enzymes for industrial and therapeutic use, achieving catalytic efficiencies exceeding natural variants by orders of magnitude, as evidenced in protein engineering for novel antibiotics.^[134] These tools, combined with high-throughput screening, have illuminated evolutionary principles and causal mechanisms in biomolecular interactions, driving empirical validation of structure-function relationships. Stem cell-derived organoids, advanced since the 2010s, model human tissues in vitro with fidelity to native physiology, aiding dissection of developmental biology and pathogenesis without reliance on animal models.^[131] Collectively, these innovations underscore biotechnology's empirical contributions to dissecting biological causality, though source evaluations must account for institutional incentives potentially skewing interpretations toward overstated therapeutic potentials.^[4]

Risks, Criticisms, and Controversies

Biosafety and Health Risks

Biosafety in biotechnology encompasses protocols to prevent unintended exposure to or release of biological agents, classified into Biosafety Levels (BSL) 1 through 4 based on agent risk and containment requirements.^[135] Laboratory-acquired infections and containment breaches have occurred historically, with human error contributing to 67-79% of potential exposures in BSL-3 facilities as of 2019 analyses.^[136] Between 1975 and 2016, at least 71 documented incidents involved accidental or intentional high-risk pathogen exposures, including infections from agents like Ebola and SARS.^[137] Notable examples include the 1977 re-emergence of H1N1 influenza, which caused an estimated 700,000 deaths worldwide and was traced to a laboratory escape during vaccine research, and the 1979 Sverdlovsk anthrax outbreak in the Soviet Union, linked to a military bioweapons facility failure resulting in at least 66 deaths.^[138] These events underscore causal vulnerabilities in containment systems, though rigorous BSL protocols and dual-use research oversight have reduced incidence rates over time, with global mappings from 2000-2021 identifying fewer than 300 reported breaches despite expanded biotech activity.^[139] Health risks from biotechnological products primarily involve potential toxicity, allergenicity, or unintended genetic effects, though empirical data from long-term studies indicate low realized hazards. Genetically modified organisms (GMOs) in food and agriculture, cultivated commercially since 1996, show no evidence of unique health dangers in peer-reviewed meta-analyses; for instance, a 2014 review of 147 studies found GM adoption reduced pesticide use by 37%, boosted yields by 22%, and yielded no substantiated links to cancer, obesity, or organ damage after over 1.78 billion years of collective animal feeding exposure.^[140]^[141] Twenty-eight years of GMO deployment as of 2024 have produced no verified consumer harm, with regulatory assessments confirming compositional equivalence to non-GM counterparts and negligible allergen transfer risks under current testing.^[142] Criticisms alleging toxicity or antibiotic resistance transfer from GM plants persist in some advocacy literature, but these lack causal validation in controlled trials and often stem from methodological flaws in outlier studies dismissed by consensus reviews.^[143] In advanced applications like CRISPR-Cas9 gene editing, off-target effects—where the nuclease cleaves unintended genomic sites—pose theoretical risks of mutations leading to oncogenesis or heritable changes, with early studies detecting rates exceeding 50% in some cellular models.^[144] However, refined guide RNAs, high-fidelity Cas9 variants, and predictive algorithms have reduced off-target activity to near-undetectable levels in recent iterations, and ongoing clinical trials for conditions like sickle cell disease report no adverse events attributable to such effects as of 2023, though long-term surveillance remains essential due to incomplete understanding of epigenetic repercussions.^[145]^[146] Biotechnological vaccine platforms, such as mRNA and viral vectors, carry rare acute risks including thrombosis with thrombocytopenia syndrome (TTS) observed in approximately 1-2 per million doses of certain adenovirus-based COVID-19 vaccines, causally linked via platelet factor 4 antibodies, and myocarditis at rates of 1-10 per 100,000 in young males post-mRNA dosing. These events, while prompting enhanced screening, represent fractional risks against baseline infection hazards, with no evidence of broader genomic integration or fertility impacts from large-scale pharmacovigilance data. Antibiotic resistance, exacerbated by clinical overuse rather than direct biotech engineering, sees biotechnological interventions like phage therapy and synthetic biology countermeasures showing promise in preclinical models without amplifying resistance dissemination.^[147] Overall, while theoretical pathways to harm exist, causal evidence prioritizes mitigated risks over systemic threats, tempered by source biases in alarmist reporting from non-peer-reviewed outlets.

Environmental Concerns

One primary environmental concern with genetically modified (GM) crops involves gene flow, where transgenes transfer to wild relatives or non-GM crops via cross-pollination or seed dispersal, potentially leading to reduced genetic diversity in wild populations. Documented cases include gene flow from GM canola to wild mustard in Canada and from GM rice to weedy rice in China, raising risks of creating hybrid weeds with enhanced fitness.^[148] ^[149] However, comprehensive reviews indicate that while gene flow occurs, its long-term ecological impacts on biodiversity are often limited and context-dependent, with no widespread evidence of irreversible harm to ecosystems as of 2017 assessments.^[150] The widespread adoption of herbicide-tolerant GM crops, such as those engineered for glyphosate resistance, has contributed to the evolution of herbicide-resistant "superweeds," necessitating increased herbicide use and tillage, which can degrade soil health and biodiversity. By 2023, over 250 weed species globally exhibited resistance to multiple herbicides, partly linked to GM crop management practices in the Americas.^[151] ^[148] Empirical data from long-term field studies show mixed outcomes: while some regions report heightened weed pressure, others demonstrate net reductions in overall pesticide applications due to precise targeting enabled by GM traits.^[150] In biofuel production, biotechnology-driven expansion of dedicated crops like corn ethanol and palm oil biodiesel has induced indirect land use changes, including deforestation and conversion of grasslands, elevating greenhouse gas emissions beyond fossil fuel baselines in certain scenarios. Life-cycle analyses estimate that indirect land use change (ILUC) from U.S. corn ethanol added 20-50 grams of CO2-equivalent per megajoule in early models, though updated economic modeling suggests minimal direct links to tropical deforestation for North American policies.^[152] ^[153] ^[154] Synthetic biology applications, including engineered microbes for bioremediation or industrial processes, pose risks from accidental escape into natural environments, where they could outcompete native species or facilitate horizontal gene transfer, altering microbial communities. Laboratory incidents and modeling predict potential propagation with unforeseen cascading effects on soil or aquatic ecosystems, prompting calls for stringent biocontainment.^[155] ^[156] Peer-reviewed assessments highlight that while containment technologies exist, complete prevention of release remains challenging, particularly for scalable applications.^[157] Emerging tools like gene drives, which bias inheritance to spread modifications rapidly through populations, amplify environmental risks due to their self-propagating nature, potentially causing unintended suppression of non-target species or ecosystem imbalances. National Academies reports from 2016 emphasize challenges in predicting gene flow dynamics and reversibility, with field trials for mosquito control underscoring needs for spatiotemporal containment to mitigate biodiversity loss.^[158] ^[159] Risk assessments recommend ecological modeling and monitoring, as irreversible spread could disrupt food webs, though species-specific designs aim to limit off-target effects.^[160] Ethical debates in biotechnology center on the moral implications of manipulating living organisms, including concerns over human dignity, the commodification of life, and the potential for exacerbating social inequalities. Critics argue that technologies like gene editing risk "playing God" by altering fundamental aspects of human nature, while proponents emphasize therapeutic benefits grounded in empirical evidence of disease alleviation, such as CRISPR-based treatments for sickle cell anemia approved by the FDA in December 2023.^[161]^[162] These debates often invoke first-principles questions about the intrinsic value of natural biological processes versus engineered improvements, with opposition rooted in fears of unintended societal shifts toward eugenics or dehumanization.^[163]^[164] A focal point is germline gene editing, which introduces heritable changes to the human genome. The 2018 announcement by Chinese scientist He Jiankui of editing embryos to confer HIV resistance sparked global condemnation for bypassing ethical safeguards, leading to his imprisonment and calls for international moratoriums; in May 2025, scientific societies advocated a 10-year ban on such applications due to risks of off-target mutations and mosaicism, which could cause unforeseen health issues in edited individuals and descendants.^[165]^[166]^[167] Proponents counter that somatic editing—non-heritable modifications—has demonstrated safety in clinical trials, treating conditions like Leber congenital amaurosis with minimal adverse events reported in 2020 trials, suggesting germline bans may unduly hinder progress against genetic diseases.^[168]^[169] Yet, ethical analyses highlight justice concerns, as enhancements could widen class divides, with wealthier groups accessing "designer" traits unavailable to others.^[170] Stem cell research exemplifies tensions between potential cures and the moral status of embryos. Embryonic stem cells, derived from blastocysts, offer pluripotency for regenerative therapies but require destroying early-stage embryos, prompting objections that this equates to ending potential human life; adult stem cells, while less versatile, avoid such destruction and have yielded treatments like hematopoietic stem cell transplants for leukemia since the 1960s.^[171]^[172] U.S. policy under President George W. Bush in 2001 restricted federal funding to existing lines, reflecting religious and ethical views equating embryos to persons, though subsequent administrations expanded access, with induced pluripotent stem cells (iPSCs) emerging in 2006 as an ethical alternative by reprogramming adult cells without embryo use.^[173]^[174] Social debates surrounding genetically modified organisms (GMOs) in agriculture focus less on verified health risks—meta-analyses of over 1,700 studies since 1996 affirm their equivalence to conventional crops in safety—and more on corporate control, labeling, and perceived unnaturalness.^[175] Public skepticism persists, with surveys showing 37% of Americans viewing GM foods as worse for health in 2020, often tied to distrust in institutions like Monsanto, whose seed patents have led to farmer dependency via terminator technology fears, though empirical data indicates yield increases of 22% for insect-resistant maize without ecological harm.^[176]^[177] In the Global South, GM adoption lags due to regulatory hurdles and activism, yet Bt cotton in India boosted farmer incomes by 50% from 2002-2010 per peer-reviewed studies, underscoring debates over equitable benefit distribution amid patent monopolies.^[178]^[179] Intellectual property in biotechnology raises questions of patenting life forms, with the U.S. Supreme Court's 1980 Diamond v. Chakrabarty decision allowing patents on genetically engineered bacteria, extended to animals like the Harvard Oncomouse in 1988, but excluding humans to preserve dignity.^[180] Critics contend this commodifies nature, potentially stifling innovation in developing nations by enforcing royalties—biotech patents cost $1-2 billion to develop, limiting access—and eroding biodiversity through proprietary strains.^[181]^[182] Ethically, European directives bar patents violating "ordre public" if they exploit animals suffering or undermine genetic resource stewardship, balancing incentives with moral limits on owning higher life forms.^[183]^[184] Access inequities amplify social divides, as high-cost therapies like CAR-T cell treatments exceeding $400,000 per patient remain unaffordable in the Global South, where less than 1% of biotech benefits accrue despite 80% of global population, fostering a "biotech divide" that entrenches health disparities.^[185]^[8] Dual-use risks, such as bioterrorism via engineered pathogens, prompt calls for oversight, with the 2001 anthrax attacks highlighting vulnerabilities, though empirical threat assessments indicate low probability compared to natural pandemics.^[161]^[186] These issues underscore causal realities: biotechnology's causal chains from lab to society demand rigorous, evidence-based governance to mitigate harms while harnessing verified gains.^[187]

Regulation and Governance

International Agreements

The Convention on Biological Diversity (CBD), adopted on 5 June 1992 and entered into force on 29 December 1993, serves as a foundational international framework addressing biotechnology in the context of conserving biological diversity, promoting sustainable use of its components, and ensuring fair benefit-sharing from genetic resources.^[188] Article 8(g) requires parties to regulate risks from living modified organisms (LMOs) resulting from biotechnology that may harm biodiversity, while Article 19 mandates cooperation in handling biotechnology applications, including safe procedures for LMO transfers and notifications for field releases.^[189] The treaty defines biotechnology broadly as any technological application using biological systems or derivatives to produce or modify products, encompassing processes from traditional breeding to genetic engineering.^[190] As of 2025, the CBD has 196 parties, though implementation varies, with some nations critiquing its emphasis on precautionary approaches that may hinder innovation without robust risk-based evidence.^[191] The Cartagena Protocol on Biosafety, a supplementary agreement to the CBD, was adopted on 29 January 2000 in Montreal and entered into force on 11 September 2003, focusing specifically on the safe handling, transport, and use of LMOs generated through modern biotechnology, such as genetically modified crops and microbes.^[192] It establishes an advance informed agreement procedure for transboundary movements of LMOs intended for intentional release into the environment, requiring exporters to provide risk assessments demonstrating no significant adverse effects on biodiversity or human health.^[193] With 173 parties as of 2023, the protocol prioritizes the precautionary principle, allowing import bans based on potential risks even absent conclusive scientific proof of harm, which has led to debates over its impact on global agricultural trade and food security.^[194] The Nagoya-Kuala Lumpur Supplementary Protocol, adopted in 2010 and effective from 2018, complements it by addressing liability and redress for damage from LMOs, defining damage as adverse changes to conservation and sustainable use of biodiversity. The Biological Weapons Convention (BWC), opened for signature on 10 April 1972 and entered into force on 26 March 1975, prohibits the development, production, acquisition, stockpiling, or retention of microbial or other biological agents or toxins for hostile purposes, directly implicating biotechnology's dual-use potential. Article I bans such agents in quantities or types exceeding peaceful purposes, without defining specific biotechnological thresholds, relying instead on national implementation to distinguish legitimate research from weaponization risks like engineered pathogens. Ratified by 185 states parties as of 2025, the BWC lacks formal verification mechanisms, prompting ongoing review conferences to address advances in synthetic biology and gene editing that could enable covert bioweapon programs.^[195] Critics note its effectiveness hinges on self-reporting, with historical non-compliance allegations underscoring enforcement challenges in an era of rapid biotech proliferation.^[196] Other multilateral efforts, such as the Organisation for Economic Co-operation and Development (OECD)'s 1986 Recommendation on Recombinant DNA Safety Considerations, provide non-binding guidelines for harmonizing biosafety assessments across member states, influencing national regulations on contained and field uses of genetically modified organisms.^[197] Similarly, World Health Organization (WHO) norms, including the 2021 framework on human genome editing, offer advisory standards for ethical oversight of heritable modifications but lack treaty status, emphasizing risk evaluation over prohibition.^[198] These instruments collectively aim to balance biotech innovation with risk mitigation, though gaps persist in covering emerging fields like synthetic biology, where international consensus remains aspirational rather than codified.^[199]

National Policies and Examples

In the United States, biotechnology products are regulated under a coordinated framework established in 1986 and updated through executive orders, with oversight divided among the Food and Drug Administration (FDA), the United States Department of Agriculture (USDA), and the Environmental Protection Agency (EPA). The FDA evaluates food and drug safety from genetically engineered plants and animals, the USDA assesses risks to agriculture from plant pests or diseases, and the EPA regulates pesticidal substances produced by biotech crops; this product-based approach focuses on safety and risk rather than the modification process itself.^[200]^[201] In May 2024, the agencies issued a joint regulatory plan to streamline approvals for categories like microbial products and gene-edited plants, aiming to reduce redundancies while maintaining safety standards.^[202] The European Union employs a precautionary, process-based regulatory regime for genetically modified organisms (GMOs), requiring pre-market authorization under Directive 2001/18/EC for environmental releases and Regulation (EC) No 1829/2003 for food and feed uses, with mandatory labeling for products containing more than 0.9% approved GM material.^[203] This framework emphasizes potential long-term risks, leading to fewer GMO approvals compared to other regions; however, in February 2024, the European Parliament voted to exempt certain gene-edited crops from stringent GMO rules if no foreign DNA is introduced, reflecting pressures to align with global competitiveness.^[204] National variations exist, such as Germany's opt-out provisions under EU rules, but overall implementation prioritizes traceability and public consultation.^[203] China has pursued an aggressive biotechnology policy to bolster food security and innovation, issuing guidelines in 2022 for safety assessments of gene-edited crops that treat them similarly to conventional breeding if no transgenes are present, under the Ministry of Agriculture and Rural Affairs.^[205] The 2021 Biosecurity Law strengthened oversight of high-risk biotech activities, including human germline editing, following ethical controversies like the 2018 CRISPR baby scandal, which prompted civil penalties and ethical guidelines in 2020.^[206] In February 2025, new guidelines promoted gene-editing tools for crops like wheat and soybeans, with over 20 gene-edited varieties approved for trials by 2023, positioning China as a leader in applied biotech despite concerns over transparency in state-driven research.^[207] In India, biotechnology regulation falls under the 1989 Rules for the Manufacture, Use, Import, Export, and Storage of Hazardous Microorganisms, Genetically Engineered Organisms, and Cells, administered by the Genetic Engineering Appraisal Committee (GEAC) within the Ministry of Environment, Forest and Climate Change, focusing on environmental and health biosafety for GM crops.^[208] Bt cotton, approved in 2002, remains the only commercialized GM crop, with approvals for GM mustard stalled by litigation over long-term ecological impacts; in June 2025, the Supreme Court urged formulation of a comprehensive national policy to balance science-based approvals with risk assessment.^[209] This cautious stance reflects public and activist opposition, contrasting with faster adoption in neighboring countries.^[210] Brazil exemplifies a Latin American approach with its 1995 Biosafety Law and 2005 GMO-specific legislation, creating the National Biosafety Technical Commission (CTNBio) to evaluate and approve biotech products, resulting in widespread GM soybean and corn cultivation covering over 50 million hectares by 2023.^[211] Policies emphasize economic benefits for agribusiness while requiring containment measures for biodiversity hotspots, though enforcement challenges persist in illegal plantings.^[211]

Future Prospects

Emerging Technologies

Advanced gene editing technologies, building on CRISPR-Cas9, have progressed to include base editing, prime editing, and large-scale DNA engineering, enabling precise modifications with reduced off-target effects.^[212]^[213] In clinical applications, CRISPR-based therapies like Casgevy received FDA approval in December 2023 for sickle cell disease, with EMA approval following in February 2024, marking the first approved gene-editing treatment for a genetic disorder.^[214] By June 2025, Eli Lilly acquired Verve Therapeutics to advance CRISPR therapies for cardiovascular diseases, reflecting growing investment in in vivo editing for conditions like high cholesterol.^[81] These tools now support brain editing and pain management strategies, with preclinical innovations addressing specificity and efficacy challenges.^[215]^[216] The integration of artificial intelligence with biotechnology has accelerated protein design, drug discovery, and predictive modeling, with AI platforms reducing R&D timelines and costs in pharmaceutical development.^[217]^[218] In 2025, AI-driven tools are applied to engineer enzymes for therapies and biodegradable materials, while enhancing precision in clinical trials and synthetic biology workflows.^[219]^[220] This convergence supports innovations in gene and cell therapies, biocomputing, and personalized medicine, though empirical validation remains essential to distinguish viable applications from overhyped projections.^[221]^[222] Synthetic biology breakthroughs enable the design of custom organisms for sustainable applications, such as microbes converting waste into biofuels or pharmaceuticals.^[223] Advances in 2025 include AI-assisted pathway engineering for agriculture and medicine, with DARPA initiatives focusing on rapid pathogen detection and field diagnostics.^[224]^[225] These developments prioritize causal mechanisms in biological systems, yielding verifiable outcomes like engineered yeast for biofuel production over speculative redesigns.^[226] Microphysiological systems, including organs-on-chips and organoids, simulate human tissues for drug testing and disease modeling, reducing reliance on animal models.^[227] In April 2025, the FDA issued guidance promoting organoids and chips to phase out certain animal trials, enhancing predictive accuracy for metabolism and drug interactions. Recent platforms, such as the AVA Emulation System introduced in 2025, integrate multi-organ emulation for advanced toxicity screening, while tumor-on-a-chip models reveal immunotherapy dynamics in vascularized environments.^[228]^[229] These technologies leverage empirical tissue engineering principles to replicate physiological responses, supporting regenerative medicine progress.^[230]^[231]

Challenges and Opportunities

Biotechnology faces significant financial hurdles, with the average cost to develop and bring a new drug to market exceeding $2 billion as of 2025, compounded by funding constraints and a challenging investment environment where venture capital inflows have declined amid macroeconomic pressures and high interest rates.^[232] Regulatory complexities further impede progress, as evolving frameworks for advanced therapies like gene editing demand extensive compliance efforts, often extending development timelines beyond a decade for many candidates.^[233] Talent acquisition remains strained, with a competitive job market where positions have decreased from approximately 19,000 in early 2022 to 10,000 by late 2023, exacerbating shortages in specialized skills for bioinformatics and bioprocessing.^[234] These challenges are intensified by high clinical trial failure rates, where only about 10% of candidates in Phase I advance to approval, driven by biological uncertainties and rigorous safety requirements.^[235] Despite these obstacles, biotechnology offers substantial opportunities through technological convergence, particularly the integration of artificial intelligence with genomic tools, enabling faster drug discovery and personalized medicine applications projected to drive sector growth from $483 billion in 2024 to $546 billion in 2025.^[236] Advances in CRISPR-based gene editing and regenerative therapies present pathways to treat previously intractable diseases, such as rare genetic disorders, with clinical successes in areas like CAR-T cell therapies demonstrating efficacy rates exceeding 80% in certain leukemias.^[237] Industrial biotechnology holds promise for sustainable solutions, including bio-based materials and biofuels that could reduce reliance on fossil fuels, addressing environmental pressures while tapping into a market expected to expand amid global decarbonization efforts.^[238] Emerging roles in precision health, such as radioligand therapeutics and antibody engineering, are attracting investment, with biopharma leaders anticipating digital innovations to streamline R&D and enhance outcomes in oncology and neurology.^[239] Overall, strategic adaptations like public-private partnerships and streamlined regulations could mitigate risks, positioning biotechnology to deliver transformative impacts on healthcare and industry by leveraging empirical advancements over hype-driven narratives.^[240]

References

[1]
Biotechnology: the view from the FDA - PubMed
FDA's working definition of biotechnology is the application of biological systems and organisms to technical and industrial processes. This definition is ...
[2]
An Introduction to Biotechnology - PMC - NIH
It is an amalgamation of biological science with engineering whereby living organisms or cells or parts are used for production of products and services. The ...
[3]
Biotechnology in the Realm of History - PMC - NIH
As per one definition biotechnology is, “Application of the principles of engineering and biological science to create new products from raw materials of ...
[4]
The relevance of the history of biotechnology for healthcare - NIH
Jan 2, 2025 · Biotechnology has revolutionized medical research, drug development and treatment across fields like precision medicine, cancer therapy, and vaccine ...Missing: definition | Show results with:definition<|separator|>
[5]
[PDF] Use of biotechnology in agriculture--benefits and risks - CTAHR
What is biotechnology, and how is it used in agriculture? Biotechnology is the application of scientific techniques to modify and improve plants, animals ...<|control11|><|separator|>
[6]
Scientific mistakes from the agri-food biotech critics
Dec 10, 2018 · Being devoid of epistemological value and bereft of empirical evidence, the demand to enforce severe restrictions on NBTs as a whole has no ...
[7]
Biotechnology, Genetic Engineering, and “GMOs:” Why all ... - IFT.org
Sep 12, 2018 · Biotechnology, genetic engineering, and related techniques and technologies have been subject to controversy and misinformation.
[8]
The worsening divergence of biotechnology: the importance of risk ...
Aug 30, 2023 · This paper explores the role of risk culture as a fundamental factor contributing to this divergence. It aims to assess the risks and benefits associated with ...Missing: empirical | Show results with:empirical
[9]
Biotechnology - Internal Market, Industry, Entrepreneurship and SMEs
As defined by the OECD, biotechnology applies science and technology to living organisms, as well as parts, products and models of them, to alter living or non- ...Missing: authoritative | Show results with:authoritative<|separator|>
[10]
What is Biotechnology? | BIO
Biotechnology is technology based on biology - biotechnology harnesses cellular and biomolecular processes to develop technologies and products that help ...<|control11|><|separator|>
[11]
History, scope and development of biotechnology - Book chapter
Hungarian engineer Karl Ereky first coined the term 'biotechnology' in 1919, meaning the production of products from raw materials with the aid of living ...Abstract · Introduction · Biotechnology and its various... · Biotechnology techniques
[12]
Scope of Biotechnology with Branches and Careers - Microbe Notes
May 21, 2024 · The biotechnology industry offers diverse career opportunities in various sectors, including research and development (R&D), manufacturing, regulation, and ...Biotechnology Historical... · Branches of Biotechnology · Scope and Career...
[13]
Biotechnology - an overview | ScienceDirect Topics
Biotechnology is defined as the use of biological processes, organisms, or systems to develop products and technologies, particularly in medicine, agriculture, ...
[14]
Aims & Scope | Nature Biotechnology
Aims & Scope · Genetic engineering · Large-scale approaches · Proteomics · Metabolomics · Computational biology · Molecular engineering · Metabolic engineering.
[15]
Principles of Biotechnology - BYJU'S
Nov 27, 2020 · The principle of genetic engineering is to manipulate and modify the genetic material of an organism to incorporate desirable traits.
[16]
Define the principles of biotechnology. | CK-12 Foundation
Two core principles of biotechnology are: Genetic Engineering: This is the technique of altering an organism's genetic material using biotechnology to create ...
[17]
10.1: Principles of Medical Biotechnology - Biology LibreTexts
Jul 9, 2025 · Medical biotechnology is a branch of biotechnology that focuses on using living cells, cell materials, and biological processes to develop ...
[18]
1972: First Recombinant DNA
Apr 26, 2013 · The first production of recombinant DNA molecules, using restriction enzymes, occurred in the early 1970s.
[19]
Personal Reflections on the Origins and Emergence of Recombinant ...
The emergence of recombinant DNA technology occurred via the appropriation of known tools and procedures in novel ways that had broad applications.
[20]
Recombinant DNA in the Lab | Smithsonian Institution
By the early 1970s, investigators had isolated several plasmids as well as special enzymes known as “restriction endonucleases” that work like scissors to cut ...
[21]
Polymerase Chain Reaction (PCR) Fact Sheet
Aug 17, 2020 · The polymerase chain reaction (PCR) is a fast and inexpensive technique used to "amplify" - copy - small segments of DNA.<|separator|>
[22]
Polymerase Chain Reaction (PCR) - StatPearls - NCBI Bookshelf - NIH
Jul 7, 2025 · PCR is widely used in basic and biomedical sciences due to its high sensitivity, specificity, and rapid processing time, making it valuable in ...
[23]
The Discovery of PCR: ProCuRement of Divine Power - PMC - NIH
In the research laboratory, PCR has become indispensible for genetic cloning, sequencing and measurement of gene expression, among a myriad of other uses. In ...
[24]
What are genome editing and CRISPR-Cas9?: MedlinePlus Genetics
Mar 22, 2022 · Genome editing changes DNA, while CRISPR-Cas9 is a specific, efficient method using a bacterial immune defense system.
[25]
CRISPR/Cas9 therapeutics: progress and prospects - Nature
Jan 16, 2023 · CRISPR gene-editing technology facilitates gene editing in eukaryotic cells. Researchers have studied the mechanism of action of Cas9 and have ...
[26]
Mechanism and Applications of CRISPR/Cas-9-Mediated Genome ...
Aug 21, 2021 · The mechanism of CRISPR/Cas-9 genome editing contains three steps, recognition, cleavage, and repair.
[27]
Bioreactor: Design, Principle, Parts, Types, Uses, Diagram
May 23, 2024 · A bioreactor is a type of fermentation vessel that is used for the production of various chemicals and biological reactions.
[28]
Exploring Principles of Bioreactor Scale-Up - BioProcess International
Feb 7, 2024 · Bioreactor scale-up influences physical, chemical, and biological factors of cell culture. Physical factors, as mentioned above, include ...
[29]
Large-Scale Production of Monoclonal Antibodies - NCBI - NIH
Commercial-scale production is generally performed to produce mAb for three purposes: diagnosis, therapy, and research on and development of new therapeutic ...MONOCLONAL ANTIBODY... · IN VIVO AND IN VITRO... · IN VIVO PRODUCTION
[30]
Monoclonal antibody production: Process, Technologies & Steps
May 4, 2023 · The production of monoclonal antibodies involves several key steps: immunization, hybridoma production, screening and cloning, and monoclonal ...03.01.Hybridoma technique in... · 03.03.Single B-cell... · 04.Production steps in...
[31]
Science & Tech Spotlight: Synthetic Biology | U.S. GAO
Apr 17, 2023 · Synthetic biology combines engineering principles with existing biotechnology techniques, such as DNA sequencing and genome editing, to modify ...
[32]
Ancient biotechnology - Science Learning Hub
Jul 6, 2022 · Early examples of biotechnology include breeding animals and crops, and using microorganisms to make cheese, yoghurt, bread, beer and wine.<|separator|>
[33]
A Giant-Sized History Of Biotechnology - Brian D. Colwell
Jun 1, 2017 · 9,000-8,000 BCE: Early evidence of beer brewing emerges in the Near East, showing humans discovered fermentation processes. Sheep ...Missing: facts | Show results with:facts
[34]
22.5B: Early Biotechnology- Cheese, Bread, Wine, Beer, and Yogurt
Nov 23, 2024 · Cheese production began around 4,000–7,000 years ago when humans began to breed animals and process their milk. Fermentation, in this case, ...
[35]
A Chronology Of Biotechnology's Ancient Era (Pre-1800)
Jun 25, 2025 · 13th-14th centuries: Agricultural innovations spread through medieval Europe including three-field crop rotation and improved animal breeds.Missing: facts | Show results with:facts
[36]
A short history of beer brewing: Alcoholic fermentation and yeast ...
Nov 21, 2022 · Brewers in ancient times were dependent on the climate and ambient temperature as well as spontaneous fermentation before the establishment of ...
[37]
Louis Pasteur | Science History Institute
His research, which showed that microorganisms cause both fermentation and disease, supported the germ theory of disease at a time when its validity was still ...
[38]
Louis Pasteur, the Father of Immunology? - PMC - PubMed Central
Pasteur's most important contribution in this paper is that the yeast can actually increase extensively in weight and produce alcohol even in a liquid that ...
[39]
Louis Pasteur: The Father of Fermentation - Explore Yeast
Pasteur discovered that certain organisms, including yeasts, were able to live in the absence of air. · He demonstrated that micro-organisms appear and grow not ...
[40]
Looking Back: A Short History of the Discovery of Enzymes and How ...
Büchner, “Eduard Büchner – Nobel Lecture: Cell-free fermentation,” can be found under https://www.nobelprize.org/prizes/chemistry/1907/buchner/lecture/, 1907.
[41]
https://www.nobelprize.org/prizes/chemistry/1907/buchner/lecture/
[42]
Gregor Johann Mendel and the development of modern ... - NIH
Jul 18, 2022 · Each of the traits Mendel studied was controlled by a single gene. This simple pattern of inheritance is now referred to as “Mendelian genetics” ...
[43]
Gregor Mendel's legacy in quantitative genetics - PMC - NIH
Jul 19, 2022 · Mendel's experiments on plant hybridization have laid the foundation of modern quantitative genetics. Mendel was well aware of the significance ...
[44]
Acetone production during the First World War | Microbiology Society
May 29, 2014 · When the Americans joined World War I, the US Army decided to convert two distilleries in Terre Haute, Indiana, into acetone plants. Nathaniel ...
[45]
How Biotechnology Helped Maintain the Supply of Acetone for the ...
Jul 31, 2014 · Acetone was needed as a gelatinizing agent to incorporate the chemical components during cordite manufacture. At the start of World War I the ...
[46]
Alexander Fleming Discovery and Development of Penicillin
In 1928, at St. Mary's Hospital, London, Alexander Fleming discovered penicillin. This discovery led to the introduction of antibiotics that greatly reduced ...Alexander Fleming's Discovery... · Scaling-up Production · Penicillin, WWII and...
[47]
Alexander Fleming (1881–1955): Discoverer of penicillin - PMC - NIH
Although Fleming published the discovery of penicillin in the British Journal of Experimental Pathology in 1929, the scientific community greeted his work ...
[48]
Historical and Policy Timelines for Recombinant DNA Technology
TABLE B-1Timeline of Key Developments in rDNA Technology During the Late 1960s and Early 1970s ; 1972, Jackson and colleagues create the first chimeric DNA in ...
[49]
Herbert W. Boyer and Stanley N. Cohen | Science History Institute
By inventing recombinant-DNA technology, Boyer and Cohen jump-started the biotechnology industry, including Genentech, which creates important applications ...
[50]
Stanley Cohen and Herbert Boyer, 1972 - DNA Learning Center
Stanley Cohen and Herbert Boyer's historic experiment used techniques to cut and paste DNA to create the first custom-made organism containing recombined or ...
[51]
Asilomar and Recombinant DNA: The End of the Beginning - NCBI
On September 10, 1974, the committee appointed to organize the February 1975 Asilomar meeting gathered in room E17 of the MIT Center for Cancer Research. The ...THE 1973 GORDON... · THE ACADEMY'S TURN · THE ASILOMAR CONFERENCE
[52]
Summary statement of the Asilomar conference on recombinant ...
Proc Natl Acad Sci USA. 1975 Jun;72(6):1981–1984. doi: 10.1073/pnas.72.6.1981 Summary statement of the Asilomar conference on recombinant DNA molecules.
[53]
Asilomar 1975: DNA modification secured - Nature
Sep 17, 2008 · The California meeting set standards allowing geneticists to push research to its limits without endangering public health.
[54]
Proof of Concept - Genentech
Apr 7, 2016 · When Bob Swanson and Herb Boyer founded Genentech in 1976, their goal was audacious: to create a business based on manipulating the genes of microorganisms.
[55]
Cloning Insulin - Genentech
Apr 7, 2016 · In 1978, Genentech scientist Dennis Kleid toured a factory in Indiana where insulin was being made from pigs and cattle.
[56]
The Discovery of Insulin: An Important Milestone in the History of ...
Oct 23, 2018 · Genentech rDNA human insulin obtained on 24th August, 1978 from combination of A and B chains individually expressed in E. coli.
[57]
100 Years of Insulin - FDA
Jun 8, 2022 · In 1978 scientists at City of Hope and Genentech developed a method for producing biosynthetic human insulin (BHI) using recombinant DNA ...
[58]
Stan Cohen | Stanley N. Cohen Lab | Stanford Medicine
Jan 24, 2019 · The DNA cloning approaches that Cohen and Boyer invented, which have become, known as recombinant DNA technology, were patented by Stanford and ...<|separator|>
[59]
Recombinant Drugs | National Museum of American History
Recombinant drugs, like Humulin insulin, are made using recombinant DNA technology. Examples include Intron A, Recombivax HB, and Activase.Missing: commercial | Show results with:commercial
[60]
History of Genetic Engineering and the Rise of Genome Editing Tools
1970s: Genetic Engineering Takes Off Unexpectedly. By 1972, researchers had created the first chimeric recombinant DNA cloning SV40 molecule into plasmid DNA. ...
[61]
The Human Genome Project
Mar 19, 2025 · Launched in October 1990 and completed in April 2003, the Human Genome Project's signature accomplishment – generating the first sequence of ...
[62]
Human Genome Project Fact Sheet
Jun 13, 2024 · In 2003, the Human Genome Project produced a genome sequence that accounted for over 90% of the human genome. It was as close to complete as the ...
[63]
The evolution of next-generation sequencing technologies - PMC
NGS technology started with the development of pyrosequencing [8] and was first commercially available in 2005 as the 454/Roche platform [9].
[64]
The Evolution of DNA Sequencing Costs: Insights from 2001 to 2022
Feb 4, 2025 · The medium cost to sequence a human genome was over USD 95 million in 2001. By 2022, that cost dropped to USD 525 a staggering decrease of 99.99%.Missing: 2000-2025 | Show results with:2000-2025
[65]
DNA Sequencing Costs: Data
May 16, 2023 · Data used to estimate the cost of sequencing the human genome over time since the Human Genome Project.Missing: 2000-2025 | Show results with:2000-2025
[66]
CRISPR–Cas9: A History of Its Discovery and Ethical ... - NIH
Aug 15, 2022 · 1987 – Short DNA repeats, later called CRISPR, were first noticed in bacterial genomes, and, in 1995, also found in archaea.
[67]
Origins of CRISPR: How it Came to Be - BioAgilytix
CRISPR-Cas9 was first used as a gene-editing tool in 2012. In just a few years, the technology has exploded in popularity thanks to its promise of making gene ...Missing: date | Show results with:date
[68]
A Tour of Key Milestones in Synthetic Biology - Telesis Bio
Aug 25, 2021 · First synthetic cell: By 2010, this team had built another a synthetic genome and raised the stakes by inserting it into a cell of a different ...Missing: present | Show results with:present
[69]
Milestones in synthetic (micro)biology | Nature Reviews Microbiology
Apr 16, 2014 · Since its debut in 2000, the field has undergone periods of rapid growth, interspersed with periods of stagnation owing to the difficulties of ...Missing: present | Show results with:present
[70]
The Long History of mRNA Vaccines | Johns Hopkins
Oct 6, 2021 · Messenger RNA, or mRNA, was discovered in the early 1960s; research into how mRNA could be delivered into cells was developed in the 1970s.
[71]
mRNA vaccines — a new era in vaccinology - Nature
Jan 12, 2018 · Recent improvements in mRNA vaccines act to increase protein translation, modulate innate and adaptive immunogenicity and improve delivery.
[72]
The rise of the genome and personalised medicine - PMC - NIH
This article provides a brief overview of genomics and its current clinical applications, including its contribution to personalised medicine.
[73]
Personalized Medicine - National Human Genome Research Institute
Personalized medicine is an emerging practice of medicine that uses an individual's genetic profile to guide decisions made in regard to the prevention, ...
[74]
Personalized medicine is coming, but who will have access to it?
Mar 7, 2024 · Experts warn that new technologies that tailor health care to individuals may exacerbate health inequities.
[75]
Monoclonal Antibodies: FDA History, Use & Future - Allucent
In 1986, Orthoclone OKT3® (muromonab-CD3) became the first monoclonal antibody approved by the FDA. Its production was based on the Nobel-winning work of Kohler ...
[76]
History of Monoclonal Antibodies: Köhler & Milstein - KCAS Bio
Jun 12, 2024 · The first humanized monoclonal antibody was approved by the FDA in 1997, and to date, over 100 humanized antibodies have been described either ...Missing: timeline | Show results with:timeline
[77]
Approved Cellular and Gene Therapy Products - FDA
Aug 15, 2025 · Approved Products ; YESCARTA (axicabtagene ciloleucel), Kite Pharma, Incorporated ; ZEVASKYN (prademagene zamikeracel), Abeona Therapeutics, Inc.
[78]
[PDF] Are Cell and Gene Therapy programs a better bet? - newdigs
Oct 9, 2023 · Orphan gene therapies are 2 – 3.5X as likely to be approved when entering Phase I as the average drug in clinical trials, outperforming in ...Missing: first | Show results with:first
[79]
FDA Approves First Gene Therapies to Treat Patients with Sickle ...
Dec 8, 2023 · Of the 31 patients with sufficient follow-up time to be evaluable, 29 (93.5%) achieved this outcome. All treated patients achieved successful ...
[80]
Overview CRISPR Clinical Trials 2025 - Learn | Innovate | Access
Feb 28, 2025 · As of February 2025, CRISPR Medicine News monitors approximately 250 clinical trials involving gene-editing therapeutic candidates, with more than 150 trials ...
[81]
CRISPR Clinical Trials: A 2025 Update - Innovative Genomics Institute
Jul 9, 2025 · An update on the progress of CRISPR clinical trials with the latest data and a survey of the CRISPR landscape in 2025.Blood Disorders · Cancers · Diabetes
[82]
10.2: Diagnostic Biotechnology - Biology LibreTexts
Jul 9, 2025 · Diagnostic biotechnology involves the use of biological tools and techniques to detect and/or measure biomarkers associated with diseases, ...
[83]
Era of Molecular Diagnostics Techniques before and after the ...
Oct 11, 2022 · The simple and most common molecular diagnostic techniques used in the clinical laboratory were FISH, PCR, microarrays, MALDI-TOF, ELISA, and ...
[84]
Overview of Protein Microarrays - PMC - PubMed Central
Protein microarray technology is an emerging field that provides a versatile platform for the characterization of hundreds of thousands of proteins.
[85]
Integrating biotechnology into diagnostic labs: Innovations in PCR ...
The field of biotechnology has significantly contributed to progress in diagnostic laboratories, especially in the early identification of genetic disorders ...
[86]
Agricultural Biotechnology - FDA
Jul 9, 2024 · A GMO (genetically modified organism) is a plant, animal, or microorganism that has had its genetic material (DNA) changed using technology.
[87]
Agricultural Biotechnology - an overview | ScienceDirect Topics
Agricultural biotechnology is defined as the application of biotechnology to agricultural processes, involving the genetic modification of plants to enhance ...
[88]
[PDF] What is Agricultural Biotechnology? - ABSPII
For about 10,000 years , farmers have been improving wild plants and animals through the selection and breeding of desirable characteristics. This breeding.
[89]
Marker-assisted selection: an approach for precision plant breeding ...
DNA markers have enormous potential to improve the efficiency and precision of conventional plant breeding via marker-assisted selection (MAS).
[90]
Molecular Breeding and Marker-Assisted Selection | ISAAA.org
Plant breeders now use marker-assisted selection (MAS). To help identify specific genes, scientists use what are called molecular or genetic markers.
[91]
History of Agricultural Biotechnology: How Crop Development has ...
Mar 5, 2012 · Examples of these that are used today include genetic marker assisted breeding, where molecular markers associated with specific traits ...
[92]
Genetically engineered (modified) crops (Bacillus thuringiensis ...
Jun 19, 2018 · Currently, the most common Bt crops are corn and cotton (Vaek et al. 1987). In 2013, four insect-resistant Bt brinjal (eggplant) varieties were ...<|separator|>
[93]
[PDF] Roundup Ready Soybeans and Bt Field Corn
Roundup Ready soybeans and Bt field corn have been rapidly adopted by U.S. farmers, yet their approval for commercialization remains under scrutiny.
[94]
Science and History of GMOs and Other Food Modification Processes
Mar 5, 2024 · Humans use traditional modification methods like selective breeding and cross-breeding to breed plants and animals with more desirable traits.Missing: revolution | Show results with:revolution
[95]
Genetically Modified (GM) Crop Use 1996–2020 - NIH
Oct 13, 2022 · Introduction. Although the first commercial GM crops were planted in 1994 (tomatoes), 1996 was the first year in which a significant area of ...
[96]
Genetically engineered crops for sustainably enhanced food ...
Some of the GM crops that received initial FDA-approval included cotton, corn and potatoes (modification of Bacillus thuringiensis (Bt) gene, Monsanto), Roundup ...
[97]
8.2: Applications of Agricultural Biotechnology - Biology LibreTexts
Oct 8, 2025 · some of the key applications of green biotechnology include genetically-modified crops, biopesticides, biofertilizers, and phytoremediation ...
[98]
Adoption of Genetically Engineered Crops in the United States
Jan 4, 2025 · Currently, more than 90 percent of U.S. corn, upland cotton, and soybeans are produced using GE varieties. GE crops are broadly classified in ...
[99]
A Meta-Analysis of the Impacts of Genetically Modified Crops
On average, GM technology adoption has reduced chemical pesticide use by 37%, increased crop yields by 22%, and increased farmer profits by 68%.
[100]
Genetically engineered crops and pesticide use in U.S. maize and ...
Aug 31, 2016 · Over the period 1998–2011, our results show that GE variety adoption reduced both herbicide and insecticide use in maize, while increasing ...
[101]
Industrial Biotechnology: Past and Present - NCBI - NIH
Accelerating advanced chemical manufacturing by industrializing biology can drive the rapid growth of an innovative U.S. bioeconomy.
[102]
[PDF] Industrial biotechnology: Tools and applications - Zhao Group @ UIUC
Industrial biotechnology, also known as white biotechnology, is the application of modern biotechnology to the sustainable production of.
[103]
[PDF] KET – INDUSTRIAL BIOTECHNOLOGY - European Commission
Industrial/White Biotechnology uses fungi, yeasts, bacteria and/or enzymes as “cell factories” to make sustainable energy, chemicals, detergents, vitamins, ...<|separator|>
[104]
Introduction: Biocatalysis in Industry | Chemical Reviews
Jan 10, 2018 · Enzyme-mediated reactions can also offer numerous cost, efficiency, safety and environmental advantages over traditional chem. approaches.
[105]
Industrial Biotechnology Based on Enzymes From Extreme ... - NIH
Bioprocess technology is based on biocatalysis, which allows manufacture of products in bulk by utilizing enzymes, and is used in diverse sectors such as food, ...
[106]
Leading Fermentation Expertise for Scalable Enzyme… - Biocatalysts
Microbial fermentation is known to be very scalable using different microbes to economically produce ingredients at large volumes.
[107]
11.1: Applications of Industrial Biotechnology - Biology LibreTexts
Jul 9, 2025 · Industrial biotechnology uses biological systems to develop products, processes, or services for industry. At the end of this page, you will be ...Biotech Focus · Introduction · Key Areas of Industrial... · Applications of Industrial...
[108]
Industrial Biotechnology - AseBio
Industrial biotechnology can produce a wide range of products (chemicals, materials, food and beverages, biofuels and biodrugs) from bio-based raw materials.
[109]
10 Everyday uses of Biotechnology - Uk-cpi.com
Dec 2, 2015 · Industrial Biotechnology uses enzymes to make bio-based products like chemicals, ingredients, detergents, materials and biofuels.
[110]
Industrial Biotechnology Market 2025 Highlights - Statifacts
Jul 4, 2025 · The global industrial biotechnology market size was estimated at USD 585.1 million in 2024 and is projected to be worth around USD 1467.82 ...
[111]
Top "Industrial Biotechnology" companies - VentureRadar
Top "Industrial Biotechnology" Companies · Solugen · Synvitrobio · Centre for Process Innovation (CPI) · DNA Script · COLIPI · Synthace · MicroPep · Holiferm.<|separator|>
[112]
Sustaining the Future of Industrial Biotechnology | JACS Au
Jul 16, 2025 · Biocatalysis, the use of natural or engineered enzymes to facilitate chemical transformations, is central to this shift. (1,2) Enzymes operate ...
[113]
Bioremediation - an overview | ScienceDirect Topics
Bioremediation is defined as the application of microorganisms to degrade or remove environmental contaminants and pollutants. AI generated definition based ...
[114]
Recent Strategies for Bioremediation of Emerging Pollutants - NIH
Aug 19, 2022 · Bioremediation is the process of using bacteria, algae, fungi, and yeast to remove contaminated materials from the environment [18]. In the ...6. Bioremediation Of Various... · 6.1. Bioremediation For... · 6.2. Bioremediation For...
[115]
Environmental Biotechnology: Meaning, Applications and Other ...
Bioremediation refers to the productive use of microorganisms to remove or detoxify pollutants, usually as contaminants of soils, water or sediments that ...
[116]
[PDF] Bioremediation: A General Outline - IN.gov
Oct 31, 2017 · Ex-situ bioremediation is usually more successful than in-situ bioremediation. Excavation breaks soil, dramatically increasing permeability, ...
[117]
Microbes' role in environmental pollution and remediation - NIH
Bioremediation is a process through which environmental pollutant concentration is reduced to a harmless value by applying biological mechanisms primarily ...
[118]
Oil Biodegradation and Bioremediation: A Tale of the Two Worst ...
Jun 23, 2011 · Rates of biodegradation in bioremediation studies resulted in total petroleum-hydrocarbon losses as high as 1.2% per day.Missing: success | Show results with:success
[119]
What Is Bioremediation? | Examples, Types & Benefits
Bioremediation is a scientific process that applies natural organic substances and their beneficial properties to remediate contaminated groundwater and soil.
[120]
Remediation Case Studies Bioremediation
This report is a collection of nine case studies of bioremediation projects prepared by Federal agencies.
[121]
Biotechnology Market Size to Hit USD 5.71 Trillion by 2034
Jul 15, 2025 · The U.S. biotechnology market size was estimated at USD 277.67 billion in 2024 and is predicted to be worth around USD 1,028.07 billion by 2034, ...
[122]
New Report Finds Bioscience Sector Generates Over $3 Trillion for ...
Dec 2, 2024 · Key takeaways from the report include: The industry's economic impact, as measured by overall output, totaled more than $3.2 trillion in 2023.
[123]
[PDF] The Economic Impact of the U.S. Biopharmaceutical Industry:
Including the impacts it supports in other sectors of the economy, the industry supports $720 billion in value added to the economy, or 3.4 percent of U.S. GDP ...
[124]
U.S. 'industrial bioeconomy' adds $210.4B and 600K+ jobs | BIO
Jun 13, 2024 · The U.S. “industrial bioeconomy” contributed $210.4 billion to the GDP and added 643,992 domestic jobs in 2023, a report released Tuesday ...
[125]
Why Industrial Biotechnology
$$370 billion contribution to the U.S. economy (2016) · 10% growth rate each year for the past decade · 2.5% of U.S. GDP attributed to industrial biotechnology ...
[126]
[PDF] Measuring The Economic Footprint Of The Biotech Industry In Europe
The results show that the biotechnology industry has contributed €34.5 bn GVA to the growth of the European economy in 2018.<|separator|>
[127]
Benefits & Risks of Biotechnology - Future of Life Institute
Nov 14, 2018 · It follows us through childhood, with immunizations and antibiotics, both of which have drastically improved life expectancy. Biotechnology is ...
[128]
Agricultural biotechnology for sustainable food security - PMC
Farmers can adopt an integrated set of tools, such as biotech crops that are climate-resilient and can better withstand various stresses, including drought, ...
[129]
Industrial Biotechnology Offers Significant Societal Benefits, Case ...
The report estimates that the biotech approach reduces carbon dioxide emissions by 30 percent, resource consumption by 60 percent and waste by 95 percent. DSM: ...
[130]
Special Report: The birth of biotechnology - Nature
Jan 23, 2003 · Within a year, they had cloned DNA molecules made by splicing together DNA fragments of two different plasmids, thus creating recombinant DNA.Missing: key advancements timeline
[131]
Scientific Breakthroughs | National Institutes of Health (NIH)
Jun 5, 2025 · Human Genome Project · The Genetic Code · Green Fluorescent Protein · mRNA Vaccine · Gene Editing · Nobel Prizes · Gaucher Disease · Sense of Smell.Missing: key timeline
[132]
mRNA-based therapeutics: powerful and versatile tools to combat ...
May 21, 2022 · Recent rapid advances in biotechnology and molecular medicine have enabled the production of almost any functional protein/peptide in the human ...
[133]
https://www.sciencedaily.com/news/plants_animals/biotechnology/
[134]
History, Current State, and Emerging Applications of Industrial ...
The past 150 years have seen remarkable discoveries, rapidly growing biological knowledge, and giant technological leaps providing biotechnological solutions.Missing: scientific timeline
[135]
Biosafety concept: Origins, Evolution, and Prospects - PMC - NIH
Jul 10, 2025 · This paper traces the historical and conceptual development of biosafety, from its origins in pathogen containment to its expansion into broader ...
[136]
Biosafety Laboratory Issues and Failures - Domestic Preparedness
Apr 12, 2023 · According to research in 2019 by Klotz, human error caused 67-79% of incidents that led to potential BSL-3 lab exposures. The percentages came ...
[137]
High-risk human-caused pathogen exposure events from 1975-2016
Aug 4, 2021 · This paper reports on a dataset of 71 incidents involving either accidental or purposeful exposure to, or infection by, a highly infectious pathogenic agent.
[138]
Virology: A timeline of lab accidents, biological attacks ... - Le Monde
Nov 13, 2022 · A series of laboratory leaks and risky experiments have taken place since the 1970s. ... 1977 A worldwide influenza epidemic kills 700,000 people.
[139]
[PDF] Laboratory accidents and biocontainment breaches - Chatham House
Dec 12, 2023 · This paper discusses a new mapping of all reports of laboratory accidents worldwide, published between 2000 and 2021, which finds that ...
[140]
A Meta-Analysis of the Impacts of Genetically Modified Crops - NIH
Nov 3, 2014 · On average, GM technology adoption has reduced chemical pesticide use by 37%, increased crop yields by 22%, and increased farmer profits by 68%.Literature Search · Average Effect Sizes · Impact Heterogeneity And...
[141]
Use of Genetically Modified Organism (GMO)-Containing Food ...
Dec 11, 2023 · They concluded that the novel genes introduced into GMO crops pose no unique hazards to human health.Scope of Use of Glyphosate... · Risks Related to Use of... · Summary and...
[142]
Full article: Twenty-eight years of GM Food and feed without harm
Mar 12, 2024 · No new GMO has been proven to be a hazard or cause harm to human consumers. These modifications have improved crop efficiency, reduced losses to insect pests.
[143]
Genetically modified foods: safety, risks and public concerns—a ...
This review will also address some major concerns about the safety, environmental and ecological risks and health hazards involved with GM foods and recombinant ...Gm Foods-Merits And Demerits · Gm Foods: Issues With... · Traceability Of Gmos In The...
[144]
Off-target effects in CRISPR/Cas9 gene editing - PMC - NIH
The off-target effects occur when Cas9 acts on untargeted genomic sites and creates cleavages that may lead to adverse outcomes. The off-target sites are often ...
[145]
Beyond the promise: evaluating and mitigating off-target effects in ...
While ongoing clinical trials have not reported any adverse events linked to CRISPR off-target effects, it's vital to acknowledge that the long-term impact of ...
[146]
Genome-wide CRISPR off-target prediction and optimization using ...
Nov 18, 2023 · The powerful CRISPR genome editing system is hindered by its off-target effects, and existing computational tools achieved limited ...
[147]
Origin of Antibiotics and Antibiotic Resistance, and Their Impacts on ...
Antibiotic resistance is as ancient as the clinical use of antibiotics, as it has become prevalent and resistant due to the capability of drug agents acting to ...
[148]
Review Impact on environment, ecosystem, diversity and health from ...
Although the consequences of gene flow and risks to biodiversity are debatable. Risks to the environment and ecosystems can exist, such as the evolution of weed ...
[149]
Assessment of Benefits and Risk of Genetically Modified Plants and ...
In this paper, we summarize and discuss the risks and benefits of genetically modified plants and products, human health hazards by genetically transformed ...3. Plant Genetic... · 4.2. Transgenic Approaches... · 6. Biosafety Regulatory Of...<|separator|>
[150]
Environmental impacts of genetically modified plants: A review
The current state of knowledge reveals that GM crops impart damaging impacts on the environment such as modification in crop pervasiveness or invasiveness, the ...
[151]
GMOs and the Environment
The environmental impacts of introduced GMOs can be either ecological or genetic and may include: Bt maize - Problems associated with insect-resistant Bt ...<|separator|>
[152]
Biofuels and land-use changes: searching for the top model - PMC
This paper discusses the main methodologies currently used by policy-makers to take decisions on how to quantify LUCs owing to biofuel production expansion.
[153]
Biofuel production: exploring renewable energy solutions for a ...
Oct 15, 2024 · ... biofuel crops can raise concerns about land use change, deforestation, and biodiversity loss. It is critical that biofuel feedstocks are ...
[154]
Don't blame U.S. biofuels for Indonesia and Malaysia deforestation ...
Jan 23, 2020 · The analytical analyses make it clear that market-mediated responses may generate some land use change in M&I due to biofuel production in the ...<|separator|>
[155]
Synthetic Biology: Environmental Health Implications of a New Field
Engineered microbes might escape and propagate in the wild with unforeseen consequences, some say. Others caution that synthetic biology has high potential for ...
[156]
Four steps to avoid a synthetic-biology disaster - Nature
Feb 29, 2012 · It also raises the possibility that these synthetic microorganisms could escape into the environment, perhaps in large quantities.
[157]
Risks and potential rewards of synthetic biology - UNEP
Mar 21, 2019 · However, the intentional or accidental release of genetically engineered organisms into the environment could have significant negative impacts ...
[158]
Assessing Risks of Gene-Drive Modified Organisms - NCBI
Risks include questions about inheritance, gene flow, monitoring, and potential harmful effects. Ecological risk assessment is used to evaluate these risks.WHAT IS RISK? · ASSESSING... · KEY CONSIDERATIONS FOR...
[159]
Summary - Gene Drives on the Horizon - NCBI Bookshelf
The potential for gene drives to spread throughout a population, to persist in the environment, and to cause irreversible effects on organisms and ecosystems ...
[160]
Recommendations for environmental risk assessment of gene drive ...
May 25, 2022 · A series of online workshops identified nine recommendations to advance future environmental risk assessment of gene drive applications.
[161]
The 5 Most Pressing Ethical Issues in Biotech Medicine - PMC - NIH
Third-party payers, employers, providers, and policy makers face moral dilemmas relative to issues about clinical research, costs, and privacy.Missing: empirical evidence
[162]
Thinking Ethically About Human Biotechnology
Does a particular application of biotechnology protect or endanger human or individual rights? Are the benefits and burdens distributed fairly? Does ...
[163]
Ethics of Nature, Human Nature, and Biotechnology - Hastings Center
Moral views about nature—claims that nature or a natural state of affairs has value—are important in contemporary debates about biotechnology.
[164]
Bioethics and biotechnology - PMC - PubMed Central
Biotechnology is at the intersection of science and ethics. Technological developments are shaped by an ethical vision, which in turn is shaped by available ...
[165]
Archive: What's So Controversial About the First Gene-Edited Babies ...
Nov 30, 2018 · His announcement has drawn widespread criticism from the scientific community over ethical and safety concerns. We asked UCSF experts in gene ...
[166]
Scientists call for 10-year ban on CRISPR for germline gene editing
May 13, 2025 · A 10-year international moratorium on the use of CRISPR and other DNA-editing tools to create genetically modified children.
[167]
Ethical and Scientific Concerns Relating to CRISPR/Cas Gene ...
Sep 9, 2025 · The technical concerns are primarily related to off-target effects and inefficient delivery methods which can cause dangerous genetic mutations.Missing: 2018-2025 | Show results with:2018-2025
[168]
CRISPR & Ethics - Innovative Genomics Institute (IGI)
In this chapter, we survey some of the ethical issues that span uses of genome editing, and then dive into some of the key questions and concerns.
[169]
The Ethics of Human Embryo Editing via CRISPR-Cas9 Technology
Sep 20, 2024 · Concerns included cloning, generating or exacerbating health disparities, biological weapons and warfare, the effect on ethical views or norms ...<|separator|>
[170]
Gene Editing: Developments, Ethical Considerations, and Future ...
This paper focuses on recent developments in germline gene editing, the current ethical dialogue on the use of CRISPR-Cas9 and similar gene editing tools, and ...Missing: controversies | Show results with:controversies
[171]
Ethical Issues in Stem Cell Research - PMC - NIH
Apr 14, 2009 · Some people, however, believe that an embryo is a person with the same moral status as an adult or a live-born child. As a matter of religious ...
[172]
Examining the ethics of embryonic stem cell research
Opponents argue that the research is unethical, because deriving the stem cells destroys the blastocyst, an unimplanted human embryo at the sixth to eighth day ...
[173]
Stem Cells - The Hastings Center for Bioethics
Sep 11, 2023 · The main ethical and policy issues with stem cells concern the derivation and use of embryonic stem cells for research. A vocal minority of ...
[174]
The Stem Cell Debate: Is it Over? - Learn Genetics Utah
The debate over stem cell research is becoming increasingly irrelevant. But ethical questions regarding hES cells may not entirely go away.
[175]
Public views on GMOs: deconstructing the myths - PubMed Central
Public views on GMOs are ambivalent, not simply for or against, and concerns are not based on erroneous information, but rather on the institutional context.
[176]
The state of the 'GMO' debate - toward an increasingly favorable and ...
Mar 23, 2022 · This study analyzes the volume and tenor of the GMO conversation as it played out on social and traditional media between 2018 and 2020.
[177]
harmonizing the discourse on genetically modified crops - Frontiers
The fear of unnaturality is a major topic of debate among anti-GMOs. On the other hand, supporters of biotech crops argue that these crops are not unnatural and ...
[178]
Societal perceptions and attitudes towards genetically modified (GM ...
Societal attitudes towards GM foods in the MENAT region are predominantly negative. ... People in the MENAT region have poor levels of knowledge about GM crops ...
[179]
Social Disputes over GMOs: An Overview - Compass Hub - Wiley
Dec 4, 2014 · This review provides an overview of social research on genetically modified crops (GM crops), also known as genetically modified organisms ...Abstract · Democracy and public debate · Social movements and peasants
[180]
[PDF] Intellectual Property in Higher Life Forms: the Patent System and ...
There are two basic ethical objections to patenting animals de- veloped through biotechnology research: concerns with "owning life" and the notion of "species ...
[181]
Patenting of genetic material: Are the benefits to society being ... - NIH
Patent protection of intellectual property is particularly important to inventors in the biotechnology field because of the relatively high fixed cost of ...
[182]
Biotechnology, Patents, and Bioethics
This paper will discuss the issues of inventions and morality with a specific focus on biotechnology. It will review intellectual property protection.
[183]
Patenting human biological materials and data: balancing the ...
Jun 6, 2023 · This article aims to analyse the ordre public and morality exclusion in patent law to understand the extent to which such exclusion can protect the human being.
[184]
[PDF] Biotechnology, Intellectual Property, and Environmental Ethics
Relying on this respect for life ethic and also on a philosophical analysis of justifica tions for intellectual property, this Article questions the appropriate.
[185]
The Inequity of Biotechnological Impact - Cell Press
Jan 4, 2021 · Less than 1% of the developing world is positively affected by biotech, with most development in developed countries, and delayed adoption of ...<|control11|><|separator|>
[186]
Societal Concerns with Biotechnology - ThoughtCo
May 7, 2025 · The four main concerns revolve around ethical, safety, bioterrorism and environmental issues. Cite this Article.
[187]
Biotech Ethics in the Global South - Reflections.live
Gene editing technologies like CRISPR have opened new avenues in biotechnology, but in the Global South, these advancements are entangled with ethical dilemmas, ...
[188]
Text of the Convention
May 13, 2016 · Text of the Convention Full Text Arabic | Chinese | English | French | Russian | Spanish View the official source on the UN Treaties website.
[189]
Article 19. Handling of Biotechnology and Distribution of its Benefits
The Convention on Biological Diversity · Article 19. Handling of Biotechnology and Distribution of its Benefits.
[190]
[PDF] cbd-en.pdf - Convention on Biological Diversity
“Biotechnology” means any technological application that uses biological systems, living organisms, or derivatives thereof, to make or modify products or ...
[191]
List of Parties - Convention on Biological Diversity
For declarations and other notes, you may visit the United Nations Treaty Collection web site. Cartagena Protocol on Biosafety : 173 Parties (103 Signatures ) ...
[192]
The Cartagena Protocol on Biosafety
It was adopted on 29 January 2000 and entered into force on 11 September 2003. More ». Number of Parties: 173. Latest Ratifications:.What's new · Parties to the Cartagena... · About the Protocol · Text
[193]
Cartagena Protocol on Biosafety to the Convention on - UNTC
The above Protocol was adopted on 29 January 2000 by the Conference of the Parties to the Convention on Biological Diversity at the resumed session of its ...
[194]
Parties to the Cartagena Protocol and its Supplementary Protocol on ...
Mar 5, 2018 · The Cartagena Protocol on Biosafety to the Convention on Biological Diversity was adopted by the Conference of the Parties to the Convention on 29 January 2000.
[195]
The Next 50 Years: Strengthening the Biological Weapons Convention
Mar 26, 2025 · The BWC establishes a legal framework to prevent biological weapons while promoting policies and practices that protect against the deliberate ...
[196]
Rethinking the Biological and Toxin Weapons Convention? - PMC
The convention was the first arms control treaty to ban an entire class of weapons, and it has served as the absolute norm against the use of biological weapons ...
[197]
[PDF] BIOTECHNOLOGY UPDATE - OECD
The update includes a publication on NBT regulations, a Global Forum on next-gen biotechnologies, and an OECD framework for governance of emerging technologies.
[198]
WHO guidelines on human genome editing: why countries need to ...
Aug 22, 2021 · The report provides a governance framework for genome editing which countries can use to develop their own regulations.Missing: biotechnology applications
[199]
Regulation of Synthetic Biology: Developments Under the ...
Apr 9, 2020 · This paper provides an overview of international developments in biotechnology regulation, including the application of the Cartagena Protocol and relevant ...
[200]
FDA's Regulation of Plant and Animal Biotechnology Products
Apr 17, 2025 · The FDA regulates plant and animal biotechnology products in coordination with the US Department of Agriculture (USDA) and US Environmental Protection Agency ( ...
[201]
Animal and Plant ... - Unified Website for Biotechnology Regulation
The U.S. Coordinated Framework for Biotechnology outlines a comprehensive Federal regulatory policy for ensuring the safety of biotechnology products.
[202]
EPA, FDA, and USDA Issue Joint Regulatory Plan for Biotechnology
May 8, 2024 · It describes the comprehensive federal regulatory policy for ensuring the safety of biotechnology products, including how EPA, the FDA, and USDA ...
[203]
GMO legislation - European Commission's Food Safety
The building blocks of the GMO legislation are: · Directive 2001/18/EC on the deliberate release of GMOs into the environment · Regulation (EC) 1829/2003 on ...Brexit · The building blocks of the... · Transparency Regulation
[204]
European Parliament votes to ease regulation of gene-edited crops
Feb 7, 2024 · The European Parliament voted to lessen regulatory oversight of crops created through one type of DNA manipulation: gene editing.
[205]
China: Crops / Food - Global Gene Editing Regulation Tracker
2022: Ministry of Agriculture and Rural Affairs in China approved new guidelines regulating gene edited plants. 2021: Biosecurity Law of China comes into effect.
[206]
In wake of gene-edited baby scandal, China sets new ethics rules ...
Mar 7, 2023 · China answered that call in 2020 with new civil penalties for researchers who violate ethical norms surrounding gene editing. In 2021, China ...
[207]
China to develop gene-editing tools, new crop varieties in biotech ...
Feb 14, 2025 · China issued guidelines on Friday to promote biotech cultivation, focusing on gene-editing tools and developing new wheat, corn, and soybean ...
[208]
Status of research, regulations and challenges for genetically ... - NIH
The regulation of all activities related to GMOs and products derived from GMOs in India is governed by Rules, 1989 under the provisions of the Environment ...
[209]
India must develop a GM crop plan based on science - Nature
Jun 6, 2025 · India's Supreme Court has called on the central government to formulate a comprehensive national policy on the regulation and adoption of genetically modified ...
[210]
Regulatory Challenges Slow India's Progress on GM Crop Adoption
Jun 11, 2025 · In March 2025, India's Supreme Court directed the central government to develop a national policy on the regulation and adoption of GM crops.
[211]
Global regulatory policies for animal biotechnology - Frontiers
In 1995, Brazil put in place its First Biosafety Law and GMO regulations. In 2005, Brazil passed a New Law for governing GMOs, creating a new National Biosafety ...
[212]
Advances in large-scale DNA engineering with the CRISPR system
Sep 1, 2025 · Recent advances in the discovery and application of CRISPR effectors have enabled targeted gene modifications and large DNA engineering in vivo.
[213]
New CRISPR tool enables more seamless gene editing - Yale News
and improved disease modeling. Yale scientists have developed a CRISPR technology that can ...
[214]
Advancing CRISPR genome editing into gene therapy clinical trials
Ongoing research explores the potential of CRISPR technology for cancer therapies, HIV treatment and other complex diseases.
[215]
Brain editing now 'closer to reality': the gene-altering tools ... - Nature
Aug 14, 2025 · CRISPR 2.0: a new wave of gene editors heads for clinical trials · UK first to approve CRISPR treatment for diseases: what you need to know.
[216]
Advances in Therapeutic Applications of CRISPR Genome Editing ...
Jun 30, 2025 · This review highlights how CRISPR-based approaches in addressing the critical issues of specificity and long-term efficacy in pain gene therapy.
[217]
[PDF] biotechnology - 2025 TECH TRENDS REPORT • 18TH EDITION
Mar 10, 2025 · AI-powered protein design is already being applied to developing new vaccines, enzyme-based therapies, and biodegrad- able plastics. As these ...
[218]
https://finance.yahoo.com/news/ai-biotechnology-market-reach-11-142100529.html
[219]
[PDF] Top 10 Emerging Technologies of 2025
Jun 25, 2025 · Biotechnology also offers some striking additions to human health in this year's top 10. Biologically based interventions are gaining momentum ...
[220]
The convergence of AI and synthetic biology: the looming deluge
Jul 1, 2025 · This manuscript examines how AI-driven tools accelerate bioengineering workflows, unlocking innovations in medicine, agriculture, and sustainability.
[221]
Top 10 Synthetic Biology Trends in 2025 - StartUs Insights
Feb 13, 2025 · Discover the Top 10 Synthetic Biology Trends plus 20 out of 700+ startups in the field and learn how they impact your business in 2025.Gene and Cell Therapy · Gene Editing · Synthetic Vaccines · Biocomputing
[222]
AI in Pharma and Biotech: Market Trends 2025 and Beyond
Looking ahead, AI's role in biopharma will expand exponentially, especially when combined with emerging technologies like synthetic biology and quantum ...
[223]
Scientists use synthetic biology to address urgent sustainability ...
Apr 23, 2025 · “Synthetic biology advances our ability to engineer living systems to address some of the world's biggest sustainability challenges, allowing ...
[224]
Engineering Tomorrow: DARPA's Push into the Frontier of Synthetic ...
Feb 4, 2025 · Synthetic biology can give the U.S. military an edge—faster pathogen detection, better protective materials, innovative field diagnostics—and do ...
[225]
AI, Robotics & Biotechnology: 3 Game-Changing Technologies ...
Sep 8, 2025 · Moving forward, artificial intelligence will likely supercharge synthetic biology, starting with molecular, pathway, and cellular design. This ...<|separator|>
[226]
Synthetic Biology: The Next Frontier of Programmable Life
Feb 9, 2025 · Scientists can now design organisms with tailor-made functions, from microbes that synthesize pharmaceuticals to yeast engineered for biofuel ...
[227]
Human Organs-on-Chips - Wyss Institute
October 15, 2025Human Organ Chip technology sets stage for pan-influenza A CRISPR RNA therapies ... Tissue Engineering · 3D Organ Engineering · Bioinspired ...
[228]
Expanding the Frontiers of Human Biology with Organ-on-a-Chip ...
Jun 25, 2025 · The 2025 MPS World Summit marked the official introduction of the AVA Emulation System, a next-generation 3-in-1 Organ-Chip platform designed specifically for ...
[229]
https://penntoday.upenn.edu/news/tumor-chip-offers-insight-cancer-fighting-cells-immunotherapy
[230]
Editorial: Latest advancements in organ-on-a-chip technology
May 29, 2025 · This Research Topic describes some of the most recent advances in organ-on-a-chip technology that include systems designed to replicate human ...
[231]
Organoids and organs-on-chips: Recent advances, applications in ...
Apr 11, 2025 · Organoids and organs-on-chips (OoCs) are rapidly evolving technologies for creating miniature human tissue models.
[232]
Biotech Challenges: 3 Barriers Affecting Industry Progress
Sep 23, 2025 · Discover the key biotech challenges that are affecting industry progress, as well as the current state of biotechnology.
[233]
BioTech 2025: Key Trends, Innovations, and Challenges Shaping ...
Jul 15, 2025 · Breakthroughs in cell and gene therapies especially using CRISPR and mRNA, are reshaping disease treatment. Early 2025 saw the rise of mRNA ...Missing: 2020-2025 | Show results with:2020-2025
[234]
The Brutal Reality of the 2025 Biotech Job Market (and How to ...
Mar 7, 2025 · The number of positions in biotech nosedived from about 19,000 in early 2022 to just 10,000 by late 2023—effectively cutting opportunities in ...
[235]
The Future of the Biotech Industry - Thermo Fisher Scientific
Sep 15, 2025 · Biotech leaders are navigating funding constraints, regulatory pressures, and the rising complexity of clinical trials—yet resilience and ...
[236]
Biotech in 2025: Innovation, Disruption, and the Future of Healthcare
The convergence of artificial intelligence, precision medicine, and novel therapeutic modalities presents unprecedented opportunities for innovation and growth.
[237]
The State of Biotechnology in 2025: Innovations and Trends
Key trends in 2025 include expanded AI in healthcare, increased regenerative medicine, genetic diagnostics, broader genome sequencing, and CRISPR-based gene ...
[238]
The State of Industrial Biotechnology: Challenges and Opportunities ...
Feb 17, 2025 · Industrial biotechnology has long been heralded as a critical player in addressing some of the world's most pressing challenges.
[239]
Top Pharma & Biotech Growth Opportunities in 2025 - Frost & Sullivan
Mar 28, 2025 · The top 6 growth opportunities are: Radioligand Therapeutics, Antibody Therapies, IT for Price Transparency, Medical Co-pilots, APAC CDMOs, and ...<|control11|><|separator|>
[240]
2025 life sciences outlook | Deloitte Insights
Dec 10, 2024 · The life sciences industry appears poised for significant transformation in 2025, driven by digital advancements and scientific innovations.